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Introduction 
 
1. TGF-β superfamily cytokines and signal transduction pathways 
 Transforming growth factor-β (TGF-β) superfamily cytokines are the evolutionary conserved pleiotropic 
secreted cytokines, which consist of TGF-β, Activins, Nodals, Bone Morphogenetic Protein (BMP), 
Myostatins, Growth and Differentiation Factors (GDF), Anti-Muellerian Hormones (AMH) and others 
(over 30 members) (Massague J et al, 2005). Individual family cytokines have crucial roles in multiple 
processes throughout development and in the maintenance of tissue homeostasis. Subversion of signaling 
by TGF-β superfamily members has been implicated in many human diseases, including cancer, fibrosis, 
inflammation, autoimmune and vascular diseases (Dijke P et al. 2007). Among them, TGF-β is produced 
from many kinds of cells, tissues and organs, and plays important roles in regulating cell proliferation, 
differentiation, homeostasis and death (Massague J et al, 2012). 
 The active form of TGF-β initiates its signal transduction by binding to specific serine/threonine kinase 
transmembrane type I and type II receptors (Heldin CH et al, 2012; Massague J et al, 2003). Upon 
ligand-induced heteromeric complex formation, the TGF-β type II receptor transphosphorylates and 
activates TGF-β type I receptor (Activin receptor-like kinase (ALK)5). Activated TGF-β type I receptor 
phosphorylates TGF-β-specific receptor regulated SMAD (R-Smad): Smad2 and Smad3 at the C-terminal 
two serine residues of Mad homology (MH)-2 domain. Activated Smad2 and Smad3 form heteromeric 
complexes with common-mediator SMAD: Smad4 to regulate transcription of the target genes (Massague 
J et al, 2005; Heldin CH et al, 2012). Besides SMAD pathway, various kinds of protein kinases mediate 
non-SMAD pathway. TGF-β type I receptor phosphorylates various protein kinases including 
phosphoinositide 3 kinase (PI3K), mitogen-activated protein kinases (MAPKs): extracellular 
signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK (p38), which then 
phosphorylate the variable linker regions of receptor regulated SMADs (Massague J et al, 2003; Wrighton 
KH et al, 2009; Matsuzaki K et al, 2013) (Background Fig. 1).  
 
  
 
 
 
 
   
  
 
<Background Figure 1>  
   TGF-β signaling pathways
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 TGF-β R-Smads: Smad2 and Smad3 are highly homologous in their structure. They contain 2 conserved 
polypeptide segments, MH1 and MH2 domain, and connected by linker domain (Background Fig. 2 left). 
The MH1 domain is involved in DNA binding and nuclear transport, whereas the MH2 domain is 
involved in receptor-mediated Smad C-terminal phosphorylation, Smad-Smad interaction and binding 
with many different transcriptional regulators (Gaarenstroom T et al, 2014). MH1 domain has a DNA 
binding site, which recognizes Smad binding elements (SBE, 5’-CAGA-3’) and regulates transcriptions 
of the genes. However, Smad2 cannot bind directly to DNA, it regulates transcriptions of target by 
interacting with other related molecules (Matsuzaki K, 2012). C-terminal serine residues, SSXS motif in 
MH2 domain are phosphorylated by TGF-β type I receptor, whereas various kinds of phosphorylation 
sites of linker domain are phosphorylated by protein kinases including MAPK. TGF-β type I receptor and 
various kinds of protein kinases differentially regulate Smad2 and Smad3 phosphorylations in a 
context-dependent manner (Matsuzaki K et al, 2013) (Background Fig. 2 right). Linker phosphorylated 
R-SMADs through Ras-MAPK antagonize C-terminally phosphorylated R-SMADs. Ras-MAPK 
mediated Smad3 linker phosphorylation enhances cell growth and proliferation by upregulating mitogenic 
signal genes such as c-Myc gene in normal epithelial cells. By contrast, TGF-β type I receptor regulated 
Smad3 C-terminal phosphorylation is involved in cell growth inhibition by inducing growth inhibition 
genes such as p15, p21 and p27 in normal epithelial cells (Matsuzaki K, 2012 and 2013). However, 
precise roles and regulatory mechanisms of linker-phosphorylated or C-terminal-phosphorylated 
R-SMADs remain largely undetermined in immune regulation. 
 
 
<Background Figure 2> Structure of receptor regulated SMAD (R-Smad) and TGF-β signaling 
pathways via linker phosphorylated R-SMAD and C-terminally phosphorylated R-SMAD 
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2. Role of TGF-β on immune system 
 TGF-β has been recognized as the most potent immunosuppressive cytokine, suppressing the 
differentiation and function of effector immune cells and inducing suppressor immune cells in immune 
system (Li MO et al, 2006; Travis MA et al, 2014). TGF-β inhibits differentiation, activation and 
immunogenic function of innate immune cells such as immunogenic dendritic cells (DC), macrophages 
and NK cells and immune responses of adaptive effector immune cells (Flavell RA et al, 2010). TGF-β 
directly suppresses the development, differentiation and immunogenic functions and activities of various 
effector T cell subsets such as CD4+ T lymphocytes Th1 (cellular immunity), Th2 (allergic diseases and 
humoral immunity), cytotoxic CD8+ T lymphocytes (CTL) (cytotoxic immunity and anti-tumor 
immunity) and IL-17 producing CD4+ T cells: Th17 (autoimmunity). In addition to direct immune 
suppression, TGF-β indirectly suppresses effector immune cells by inducing differentiation and function 
of CD4+Foxp3+ regulatory T cells: Treg (immune surveillance) (Li MO et al, 2006 and Korn T et al, 
2009) (Background Fig. 3).  
 
  
 
 
 
 
 
 
 
 
< Background Figure 3> Effects of TGF-β on effector T cell differentiation 
 Although TGF-β is abundantly produced and activated in inflammation and tumor microenvironment, 
however, precise molecular mechanisms how TGF-β signaling regulates effector immune cell responses in 
immune diseases and cancer still remain largely unknown.  
 In my doctoral dissertation, I report the novel TGF-β signaling mechanisms for Th17 cells in rheumatoid 
arthritis which is the representative autoimmune disease, and TGF-β signaling mechanisms for 
suppressing CTL in melanoma, which is a prototypical immunogenic tumor expressing melanoma 
-associated antigens. 
 
3. Role of TGF-β signaling on Th17 in rheumatoid arthritis 
 Rheumatoid arthritis is one of autoimmune diseases, in which infiltration of the joint synovium 
membrane leads to bone and cartilage destruction. Th17 plays the pathogenic role in rheumatoid arthritis. 
IL-17A produced by Th17 enhances arthritogenic symptoms, such as inflammation, cartilage damage, 
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thrombosis and bone erosion (Korn T et al, 2009 and Pierre M et al, 2012). TGF-β had been appreciated 
as the most potent immunosuppressive cytokine, suppressing the differentiation and functions of effector 
immune cells as inducing suppressor immune cells (Li MO et al, 2006; Travis MA et al, 2014). However, 
since identified as the requisite cytokine in combination with IL-6 for the differentiation of Th17 through 
inducing a master transcription factor, RORγt and IL-17 (Veldhoen M et al, 2006; Manel N et al, 2008), 
context-dependent multidirectional roles of TGF-β have been highlighted in immune regulation, similarly 
with its roles in carcinogenesis and cancer progression (Massague J et al, 2012). Th17 is a crucial effector 
CD4+ T cell subset in inflammation, protective mechanisms against infections, tumor immunity, and 
autoimmune responses (Korn T et al, 2009; Iwakura Y et al, 2011). Crucial pathogenic role of Th17 in 
rheumatoid arthritis has been well demonstrated by numerous studies including the pioneer work showing 
the attenuation of collagen-induced arthritis (CIA) in the mice deficient in IL-17A (Nakae S et al, 2003).  
 Activated TGF-β type I receptor through TGF-β signal phosphorylates not only C-termini of R-Smads, 
but also activates various protein kinases including mitogen-activated protein kinases (MAPKs) 
(Background Fig. 1). TCR, IL-6 and TGF-beta share Ras-MAPK pathways, which induce linker 
phosphorylation of TGF-β receptor-regulated SMADs, Smad2 and Smad3. However, phosphorylation 
status of Smad2/Smad3, C-terminal and linker phosphorylation or unphosphorylation during Th17 
differentiation remains undetermined (Neurath MF et al, 2011; Liu H et al, 2013) (Backgrund Fig. 2 
right). 
 Several reports have been published regarding TGF-β signaling in Th17 differentiation as listed in 
Background Table 1. However, there are points of controversy in theses reports. Lu L et al. concluded 
that JNK and p38-mediated TGF-β signaling pathways are required for Th17 differentiation based on the 
similar inhibitory effect of inhibitors against TβRI, JNK and p38 on Th17 differentiation. However, effect 
similarity of inhibitors with TβRI/TβRII inhibition on Th17 cannot demonstrate that each targeted 
enzyme is downstream of TβRI for Th17 differentiation (Hasan M et al, 2015). Lu L et al. also addressed 
that Smad2 and Smad3 were not involved in Th17 differentiation both in vitro and in vivo using murine 
experimental encephalomyelitis (EAE) model, which is inconsistent with the other reports by Matinez GJ 
et al. and Malhorta N et al, in which they showed that Smad2 deficiency suppressed, whereas Smad3 
deficiency enhanced Th17 differentiation and EAE. Martinez GJ et al. reported that Smad3 interacted 
with RORγt to decrease, whereas Smad2 interacted with RORγt to enhance RORγt-induced Th17 
differentiation. However, mechanisms how Smad2 and Smad3 oppositely regulate RORγt-induced Th17 
differentiation were not addressed. Malhorta N et al. reported that Smad2 was essential for Th17 
differentiation by modulating IL-6 receptor (IL-6R) expression, which was not observed in my system 
(Fig. 9). Takimoto T et al. reported that TGF-β-mediated induction of RORγt was independent of both 
Smad2 and Smad3 and Ichiyama K et al. reported that the suppression of Eomesodermin by TGF-β via 
the JNK pathway is an important mechanism for Smad-independent Th17 cell differentiation using 
Smad2/3 double knockout mice, in which it is impossible to distinguish the distinct effects of Smad2 and 
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Smad3. Xial S et al. reported that TGF-β-driven Smad3 signaling enhanced by retinoic acid inhibited 
Th17 differentiation. Collectively, Smad2 seems to be an inducer, whereas Smad3 seems to be a 
suppressor of Th17, thus far. MAPK signaling pathways, which phosphorylate linker regions of R-Smads, 
play crucial roles in differentiation and functions of effector T cells (Li MO et al, 2006; Travis MA et al, 
2014; Dong C et al, 2002). Chang X et al reported that the kinases MEKK2/3 induced linker 
phosphorylation of Smad2/3, which antagonized their C-terminal phosphorylation and inhibited Th17 
differentiation, although inhibition of Smad3 C-terminal phosphorylation in MEKK2/3 double knockout 
T cells determined by CAGA-luc reporter assay and Western blotting did not seem to be significant, 
moreover, they did not examine Smad2 linker phosphorylation. However whether diverse 
phosphorylation status of R-Smads, such as linker phosphorylation or unphosphorylation affects Th17 
differentiation remains largely undetermined. 
 
<Background Table 1> Reported roles of TGF-β signaling in Th17 differentiation 
 IL-6 and other cytokines such as IL-21 and IL-23 that induce and maintain Th17 activate STAT3, a 
critical transcription factor for Th17 differentiation and the pathogenesis of autoimmune diseases 
including RA (Hirahara K et al, 2010). In contrast to the established essential roles of STAT3-mediated 
IL-6 signaling in Th17 differentiation, molecular mechanisms by which R-Smads regulate Th17 
differentiation still remain under debate. Despite their high amino acid sequence homology, Smad2 and 
Smad3 exert both redundant and distinct functions in TGF-β signaling depending on the context (Brown 
KA et al, 2007).  
  Therefore, I sought to determine the mechanisms whereby R-Smads regulate Th17 differentiation. I 
investigated the molecular mechanisms how Smad2 and Smad3 regulate the transcription of the essential 
genes for Th17 and examined the pathophysiological roles of R-Smads in Th17-related inflammatory 
disease by applying a CIA model to Smad2-deficient (Smad2-/-), Smad3-deficient (Smad3-/-), and control 
wild-type mice. I discovered the opposing functions of Smad2 and Smad3 as transcription cofactors of 
STAT3 in Th17 differentiation independently of Smad4: the canonical partner of C-terminally 
phosphorylated R-Smads. Mechanistic studies showed that phosphorylation status of R-Smads 
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distinctively modulated STAT3-induced transcription of the Rorc and Il17a genes. Linker-phosphorylated 
Smad2 (pSmad2L) at the residue Ser255 via ERK served as a STAT3 coactivator in cooperation with 
p300, whereas C-terminally unphosphorylated Smad3 (unphosphorylated Smad3C) served as a STAT3 
corepressor in cooperation with protein inhibitor of activated STAT3 (PIAS3), the negative regulator of 
STAT3 signaling. 
                 
4. Role of TGF-β signaling on CTL in melanoma 
 Tumor cells and stromal cells in the tumor microenvironment produce and activate TGF-β abundantly 
for suppressing anti-tumor immunity (Bierie et al, 2006; Flavell RA et al, 2010). TGF-β suppresses 
anti-tumor immunity by directly inhibiting the differentiation and functions of various effector cells, such as 
DC, NK, Th1, and cytotoxic T lymphocytes (CTLs) (Li MO et al, 2006). In addition to direct immune 
suppression, TGF-β indirectly suppresses anti-tumor immunity by inducing suppressor immune cell subsets, 
such as Foxp3+ regulatory T cells (Treg) and myeloid-derived suppressor cells (Flavell RA et al, 2010) 
(Background Fig. 4).  
<Background Figure 4> Inhibition of Anti-tumor Immune Responses by TGF-β 
 Varieties of TGF-β antagonists have been developed to intervene with excessive TGF-β signaling 
activity in cancer (Hata A et al, 2012). TGF-β type I receptor: activin receptor-like kinase5 (ALK5) 
inhibitors are the small molecule inhibitors, which block phosphorylation of TGF-β receptor-activated 
Smads (R-Smads) by occupying the ATP binding site of TβRI domain (Jin et al, 2011). On the basis of a 
selective, imidazole-based ALK5 inhibitor, 4-(4-(benzo[d][1,3]dioxol-5-yl)-5-(pyridin-2-yl)-1H- 
imidazol-2-yl) benzamide, SB-431542 (Callahan et al, 2002) as a lead compound, we designed and 
synthesized an orally bioavailable ALK5 inhibitor, N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5- 
(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline, EW-7197 (Kim et al, 2011) 
<Background Fig. 5>. 
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< Background Figure 5> ALK5 inhibitors (EW7197 and LY2157299) and TGF-β signaling pathway 
 
 Melanoma is a prototypical immunogenic tumor expressing melanoma-associated antigens, which are 
targeted by CTLs (Thomson et al, 1988). CTLs lyse the target tumor cells with the cytolytic molecules 
(Russell et al, 2002). The T-box transcription factors, T-bet and Eomes are crucial for the differentiation and 
effector functions of CTLs (Glimcher et al, 2004; Intlekofer et al, 2005; Pearce et al, 2003), which are 
required for anti-tumor immune responses (Zhu et al, 2010). Thus, intensive efforts have focused on 
developing immunotherapies to activate anti-melanoma T cell responses (Kirkwood et al, 2008). However, 
melanoma cells produce high amounts of TGF-β, which limit the success of immunotherapy by rendering the 
host immune response tolerant to tumor-associated antigens (Javelaud et al, 2008).  
 Therfore, I report the cellular and molecular mechanisms how EW-7197 and a representative ALK5 
inhibitor,4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolone-6-carboxami
de, LY-2157299 (Calvo-Aller et al, 2008) exert a therapeutic effect on a mouse model of B16 melanoma. 
Oral treatment with a novel ALK5 inhibitor, EW-7197 (2.5 mg/kg daily) or a representative ALK5 
inhibitor, LY-2157299 (75 mg/kg bid) suppressed the progression of melanoma with enhanced CTL 
responses. Notably, ALK5 inhibitors not only blocked R-Smads phosphorylation, but also induced 
ubiquitin-mediated degradation of the Smad4 mainly in CD8+ T cells in melanoma-bearing mice. 
Accordingly, T-cell specific deletion of Smad4 was sufficient to suppress the progression of melanoma. I 
further identified eomesodermin (Eomes), the T-box transcription factor regulating CTL functions, as a 
specific target repressed by TGF-β via Smad4 and Smad3 in CD8+ T cells. Thus, ALK5 inhibition 
enhances anti-melanoma CTL responses through ubiquitin-mediated degradation of Smad4 in addition to 
the direct inhibitory effect on R-Smad phosphorylation. 
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Phosphorylation status determines the opposing functions of 
Smad2/Smad3 as STAT3 cofactors in Th17 differentiation 
（リン酸化状態が STAT3 転写共役因子としての 
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Materials and Methods 
Mice 
Smad23loxp/3loxp mice targeting exons 9 and 10 (Liu Y et al, 2004), Smad3ex8/ex8 mice targeting exon 8 
(Yang X et al, 1999) were generated as described on Sv129 x C57BL/6J background and backcrossed to 
C57BL/6J mice (Nihon SLC) for eight generations. For in vitro experiments, Smad3ex8/ex8 mice were 
backcrossed to C57BL/6J background for four generations. I used Smad3+/- mice because Smad3-/- mice 
develop osteoarthritis, bone malformation (Yang X et al, 2001), and impaired mucosal immunity (Yang X 
et al, 1999), and the embryonic lethality of Smad3-/- mice in C57BL/6 background was extremely high, 
similarly with Tgf-β1-/- mice (Bonyadi M et al, 1997). Cd4Cre transgenic mice (Lee PP et al, 2001) were 
purchased from Jackson laboratories. Mx-1Cre transgenic mice (Kuhn R et al, 1995) were kindly provided 
by Dr. Masayuki Yamamoto (Tohoku University, Japan). For Mx-1Cre mice, gene deletion was induced 
by i.p. injection of polyI:C at 2-3 weeks of age as described previously (Campbell IK et al, 2000). For 
immunophenotyping, spleens and superficial lymph nodes (cervical, axillary, brachial, and inguinal) from 
the female mice aged between 12-16 weeks were used (age and sex matched, no randomized). All 
animals were maintained and used for experiments according to the ethical guidelines for animal 
experiments and the safety guidelines for gene manipulation experiments at Konkuk University, Korea, 
University of Tsukuba, Japan, Tokyo Medical University, Japan under approved animal study protocols.  
 
Collagen Induced-Arthritis (CIA)  
For induction of collagen-induced arthritis, I used immunization protocol for C57BL/6 strain (H-2b)  
(Campbell IK et al, 2000). Briefly, 100 µg of type II chick collagen (Sigma-Aldrich, Cat. #C9301) was 
dissolved in 10 mM acetic acid (2 mg/ml) by stirring overnight at 4°C. I dissolved 250 µg of heat-killed 
mycobacterium tuberculosis (Difco Laboratories) in incomplete Freund adjuvant (GIBCO). Type II chick 
collagen mixture gently emulsified in complete Freund adjuvant by 1:1 ratio on ice for 1 hr (100 µg of 
type II chick collagen emulsified in 100 µl of incomplete adjuvant with 250 µg of heat-killed 
mycobacterium tuberculosis). Mice aged between 8-10 weeks were injected i.d. (100 µl of emulsion) at 
several sites into the base of the tail and back that is near hind leg areas by using 26 G needle on day -21, 
and the same injection was repeated on day 0. Arthritis development in each paw was scored by 
macroscopic evaluation (Rosloiec EF et al, 2010) as: (0) no change, (1) erythema and mild swelling 
confined to the ankle, (2) erythema and mild swelling from the ankle to mid-foot, (3) moderate swelling 
(4) severe swelling. The maximum score per mouse is 16. Ten to twenty mice/genotype were used 
(Figure 1 legend and Supplementary figure 2 legend). Mice were dissected 2 weeks after the second 
immunization to evaluate the draining lymph nodes (popliteal, inguinal, axillary, and brachial).   
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Histological analysis 
Paws from collagen-immunized mice were harvested, fixed in 10% neutral-buffered formalin, decalcified, 
dehydrated with 70% ethanol, embedded in paraffin, and sectioned at 3 µm. Sections were stained with 
hematoxylin and eosin (H&E), toluidine blue, or safranin O. For immunohistochemistry, sections were 
incubated in the 60°C for overnight. Incubated sections were deparaffinized and hydrated by xylene and 
graded alcohol series (Xylene for 15 min, and 100%, 95%, 90%, 85%, 80% and 70% of EtOH for 5 min). 
After deparaffinization and hydration, tissue sections were rinsed in tap water for 10 min. Tissue sections 
were added by 3% hydrogen peroxide solution in room temperature for 30 min for peroxidase quenching, 
and washed in PBS for 5 min. After peroxidase quenching, added one or two drops of blocking solution 
(Dako, Cat.# x0590) in 37°C for 30 min. After blocking, tissue sections were incubated with rat anti-CD4 
(Abcam, Cat.# ab25475), rabbit anti-RORγt (Abcam, Cat.# ab78007), rabbit anti-IL-17A (Abcam, Cat. 
#ab79056) antibodies in 4°C for overnight, and washed in PBS for 5 min. Incubated sections from 
primary antibodies were incubated by diluted biotinlated secondary antibody in 37°C for 30 min, and 
washed in PBS for 5 min. After secondary antibody incubation, the sections were incubated with VETA 
STAIN R.T.U Elite ABC Reagent (Vector) in 37°C for 30 min, and washed in PBS for 5 min. The tissue 
sections were treated DAB solution for 5 min (according to samples), and washed in PBS for 5 min. After 
DAB exposure step, the tissue sections were incubated in hematoxylene for 1 min, and washed in tap 
water for 30 min. After counterstain step, dehydrated and mounted. Slides were observed using an optical 
microscope, DM5000B (Leica). 
 
Flow cytometry analyses 
Fluorophore-conjugated antibodies were purchased from BD Pharmingen and eBioscience 
(APC-Cy7-anti-CD4, Pacific blue-anti-CD8, APC-anti-CD25, FITC-anti-CD103, PE-anti-RORγt, 
PE-anti-T-bet, PE-Cy7-anti-Foxp3, APC-anti-IL-17A, PE-anti-IL-6, FITC-anti-TNFa, PE-Cy7-anti-IFN-γ, 
APC-anti-phospho ERK1/2, PE-anti-phospho JNK, FITC-anti-phospho p38 were used). CD16/32 were 
blocked by Fc-Block (BD Pharmingen, Cat. #553142) and isotype-matched control antibodies were used 
in each experiment. For cytokine intracellular staining, cultured Th17 cells or freshly isolated cells from 
CIA mice were treated with 5 ng/ml of phorbol-12-myristate 13-acetate (PMA) (Sigma Aldrich) and 500 
ng/ml of ionomycin (Sigma Aldrich) in the presence of GolgiPlug (BD Pharmingen) for the last 4 hours 
of culture. For intracellular staining, cultured cells were fixed by Cytoperm/Cytofix kit (BD Pharmingen). 
For Foxp3 staining, Foxp3 staining kit (eBioscience, Cat. #00-5523-00) was used. Stained cells were 
acquired and analyzed using LSR II (BD) and FlowJo software (Tree Star Inc.). 
 
T cell stimulation in vitro. 
Cell suspensions were prepared from spleens and superficial lymph nodes (cervical, brachial, axillary and 
inguinal and popliteal lymph nodes) by filtering through Cell Strainers (pore size: 40-µm diameter) (BD 
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Falcon). Erythrocytes were lysed using RBC Lysis Buffer (Rhoche) and cells were washed in PBS 
containing 2% FBS (Hyclone Laboratories). Viable cells were counted by hemacytometer using trypan 
blue exclusion. CD4+ T cells were purified to >90% by magnetic activated cell separation purification 
using CD4+ (L3T4) Microbeads (Miltenyi Biotec). In some experiments, CD44lowCD62LhighCD4+ T cells 
were sorted by FACS Aria (BD) and the purity was >98%. Purified CD4+ T cells were stimulated by 
plate-coated anti-CD3 (2.0 µg/ml; BD Pharmingen, Cat. #553057) and soluble anti-CD28 antibodies 
(5.0 µg/ml; BD Pharmingen, Cat. #553294) with mIL-6 (50 ng/ml), TGF-β1 (1 ng/ml; Peprotech), 
anti-mouse IL-4 (10 µg/ml; Biolegend, Cat. #504108) and anti-mouse IFN-γ antibodies (10 µg/ml; 
BioLegend, Cat. #505812) in 10% FCS RPMI 1640 media supplemented with penicillin and streptmycin 
(HyClone) for Th17 differentiation for 3-4 days as previously described (Veldhoen M et al, 2006). In 
some experiments, Purified CD4+ T cells were stimulated by the indicated doses of plate-coated anti-CD3, 
TGF-β1, and mIL-6, or by plate-coated anti-CD3 (10.0 µg/ml; BD Pharmingen, Cat. #553057), soluble 
anti-CD28 antibodies (5.0 µg/ml; BD Pharmingen, Cat. #553294), IL-1β (10 ng/ml; Peprotech), IL-23 
(10 ng/ml; Peprotech), and the neutralizing antibodies described above, or by the indicated doses of 
various small molecule inhibitors: EW-7197 (ALK5 inhibitor) from Dr. Dae-Kee Kim, PD98059 (MEK 
inhibitor), SP600125 (JNK inhibitor), and SB203580 (p38 inhibitor) (Sigma Aldrich). STAT3 siRNA 
(Dharmacon), PIAS3 siRNA (Santa Cruz), DNA constructs: Smad2, Smad2 (S255A), Smad3, Smad3 
(3S-A), and Smad3 (MH1+L) from Dr. Koichi Matsuzaki and Dr. Takeshi Imamura, PIAS3 (Addgene, 
submitted by Shuai), and pcDNA or control RNA were transfected to purified CD4+ T cells using 
4D-NucleofectorTM and AmaxaR Mouse T cell nucleofactorR kit (Lonza) prior to the cell culture. 
 
RNA isolation and quantitation of mRNA by real-time RT-PCR 
Total RNA was extracted using Trizol according to the manufacturer’s instructions (Invitrogen). RNA 
was reverse transcribed with cDNA reverse transcription kit (Invitrogen). Amount of cDNA was 
quantitated by SYBR green (Applied Biosystems) real time PCR using ABI 7900 and ABI 7300 
machines (Applied Biosystems). The primers are described in Table 1.  
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Table 1 Primer sequences for quantitative RT-PCR 
 
 
Western blotting and immunoprecipitation 
293T cells (ATCC-CRL-3216) were transfected using PEI with STAT3 (Addgene, submitted by J. 
Darnell), FLAG-tagged Smad2 (full length, MH1, MH1+Linker, MH2+Linker, MH2, Y220V, S245A, 
S250A, S255A) and FLAG-tagged Smad3 (full length, MH1, MH1+Linker, MH2+Linker, MH2, 3S-A) 
from Dr. Koichi Matsuzaki and Dr. Takeshi Imamura. Cells were lysed with lysis buffer (PBS containing 
0.5% Triton X-100, 20 mM HEPES (pH 7.4), 150 mM NaCl, 12.5 mM β-glycerol phosphate, 1.5 mM 
MgCl2, 10 mM NaF, 2 mM DTT, 1 mM NaOV, 2 mM EGTA, 1 mM PMSF, and protease inhibitor cock-
tail) were electrophoresed on 10% SDS-polyacrylamide gel and transferred to PVDF membrane, and 
probed with antibodies against phospho-Smad2 (Abcam, Cat. #ab53100), phospho-Smad3 (Abcam, Cat. 
#ab51451), Smad2 (Santa Cruz, Cat. #sc-101153), Smad3 (Santa Cruz, Cat. #sc-101154), Smad4 (Santa 
Cruz, Cat. #sc-7966) and β-actin (Santa Cruz, Cat. #sc-7210). Blots were visualized using an 
electrochemiluminescence kit (GE Healthcare).  
 For immunoprecipitation, the lysates were cleared by centrifugation at 16,000 g for 10 min, incubated 
with protein A/G agarose beads and with anti-STAT3 antibody (Santa Cruz, Cat. # sc-7179) at 4°C for 
12-16 h. The beads were washed three times with lysis buffer and immunoprecipitates were separated 
from the beads by adding 2× sample buffer and boiled. SDS–PAGE-separated immunoprecipitates were 
transferred onto PVDF membranes. The membranes were denatured with denaturation buffer containing 6 
M guanidine chloride, 20 mM Tris (pH 7.5), 100 mM PMSF, and 5 mM β-mercaptoethanol at 4°C for 30 
min and washed three times with TBST. The membranes were blocked with 5 % BSA and incubated with 
anti-FLAG antibody (Biomol, Cat. #ADI-SAB-410-0100). 293T cells (ATCC-CRL-3216) were 
confirmed to be mycoplasma negative using e-Myco plus Mycoplasma PCR Detection Kit (iNtRON 
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Biotechnology, Cat. #25237). 
 
Immunocytochemistry: Proximity Ligation Assay (PLA) 
CD4+ T cells cultured in Th17 condition for 3-5 days or 293T cells (ATCC-CRL-3216) transfected with 
various constructs were fixed on the slides by 3.7 % formaldehyde in PBS. The slides were washed, 
permeabilized by 0.1 % Triton X-100 in TBS and blocked by 0.5 % bovine serum albumin. PLA was 
performed using the Duolink II Fluorescence kit (OLINK) as previously described using the rabbit 
antibodies against: STAT3 (Cell Signaling Technology, Cat. #12640), phospho-STAT3 Y705 (Cell 
Signaling Technology, Cat. #9145), phospho-STAT3 S727 (Cell Signaling Technology, Cat. #9134), 
Smad2 (Cell Signaling Technology, Cat. #5339), phospho-Smad2C S465/467 (Cell Signaling Technology, 
Cat. #3101), phospho-Smad2L S245/250/255 (Cell Signaling Technology, Cat. #3104), Smad3 (Cell 
Signaling Technology, Cat. #9523), phospho-Smad3C S423/425 (Cell Signaling Technology, Cat. #9520), 
RORγt (Abcam, Cat. #ab78007), PIAS3 (Santa Cruz, Cat. #sc-14017), Flag (Biomol, Cat. 
#ADI-SAB-410-0100) and phospho-Smad3L S208/213 (IBL, Cat. #JP28029), mouse antibodies against: 
Smad2/3 (Santa Cruz, Cat. #sc-133098), Smad4 (Santa Cruz, Cat. #sc-7966), STAT3 (Santa Cruz, Cat. 
#sc-8019), and p300 (Santa Cruz, Cat. #sc-48343). Target specific rabbit primary antibodies and the 
secondary antibodies conjugated with oligonucleotides: PLA probe anti-rabbit PLUS (Sigma-Aldrich, Cat. 
#DUO92002) and PLA probe anti-rabbit MINUS (Sigma-Aldrich, Cat. #DUO92005) or PLA probe 
anti-mouse PLUS (Sigma-Aldrich, Cat. #DUO92001) and PLA probe anti-mouse MINUS 
(Sigma-Aldrich, Cat. #DUO92004) were used for single recognitions. Two primary antibodies raised in 
different species and the secondary antibodies conjugated with oligonucleotides: PLA probe anti-rabbit 
PLUS and PLA probe anti-mouse MINUS were used for double recognitions. After incubation of the 
slides with Blocking Solution for 30 min at 37°C, they were incubated with primary antibodies diluted in 
the Antibody Diluent overnight at 4°C, in PLA probe solution for 1 h at 37°C and in Ligation-Ligase 
solution for 30 min at 37°C with washing with Wash Buffer A (0.01 M Tris, 0.15 M NaCl and 0.05% 
Tween 20, filtered in a 0.22 µm) in the interim of each step. The slides were incubated in 
Amplification-Polymerase solution for 100 min at 37°C and then washed in Wash Buffer B. Nucleus was 
stained with DAPI. Then, the slides were dried at room temperature in the dark. Slides were observed 
using a confocal microscope, LSM700 (Carl Zeiss). PLA signals were quantified using BlobFinder 
software (Centre for Image Analysis, Uppsala University). 
 
Luciferase assay 
The 2000 bp promoter region of RORγt was generated by PCR from genomic C57BL/6 DNA using 
primers described in Table 2. Products were verified by sequencing and were subcloned into pGL4 firefly 
luciferase construct (Promega) using NheI, EcoRV sites and XhoI, HindIII sites respectively. The pGL4 
mIL-17 2kb promoter construct was from Addgene (submitted by W. Strober). The promoter constructs 
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in various combination with Flag-tagged STAT3 (Addgene, submitted by J. Darnell), Flag-tagged Smads, 
Flag-tagged Smad mutants, HA-tagged p300, Flag-tagged PIAS3 (Addgene, submitted by Shuai), or 
empty pcDNA3 plasmid were co-transfected with control TK-pRL Renilla plasmid using PEI for 293T 
cells or using 4D-NucleofectorTM and AmaxaR Mouse T cell nucleofactorR kit (Lonza) for Th17 cells. Six 
hours after transfection, 293T cells (ATCC-CRL-3216) were lysed for the measurement by luminometer. 
CD4+ T cells were transfected in prior to the cell culture under Th17 polarizing condition for 4 days. 
 
Table 2 Primer sequences for the proximal promoter regions 
 
 
ChIP 
Chromatin was prepared from 1x107 CD4+ T cells isolated from C57BL/6 mice, Cd4Cre;Smad2fl/fl mice, 
Smad3-/- mice and the littermate control mice under Th17 polarizing condition for 3-4 days. 
Immunoprecipitation was performed with antibodies against Smad2 (Cell Signaling Technology, Cat. 
#5339), Smad3 (Cell Signaling Technology, Cat. #9523), phospho-Smad3C S423/425 (Cell Signaling 
Technology, Cat. #9520), Smad4 (Santa Cruz, Cat. #sc-7966), STAT3 (Santa Cruz, Cat. #sc-7179), 
tri-methyl histone H3 Lys4 (Cell Signaling Technology, Cat. #9751), tri-methyl histone H3 Lys27 (Cell 
Signaling Technology, Cat. #9733), acetyl histone H3 Lys23 (Millipore, Cat. #17-10112), and PIAS3 
(Santa Cruz) using ChIP kit (Cell Signaling) according to the manufacturer’s protocol. 
Immunoprecipitated DNA released from the cross-linked proteins was quantitated by real time PCR using 
the primers (Table 3) and was normalized to input DNA. 
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Table 3 Primer sequences for ChIP 
 
 
Statistical analyses 
Statistical analysis was performed using analysis tools on the VassarStats Statistical Computation site 
(http://vassarstats.net/) and Excel. Data were analyzed using the parametric unpaired Student t-test, or 
two-way ANOVA test for CIA scoring.
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Results 
Opposing roles of Smad2 and Smad3 in the pathogenesis of CIA 
 To examine the pathophysiological roles of R-Smads in Th17-mediated inflammatory disease, I applied 
a CIA model to T cell-specific (Cd4Cre;Smad2+/+, +/fl, fl/fl), inducible systemic (Mx-1Cre;Smad2+/+, +/fl, fl/fl) 
Smad2 conditional knockout mice, and Smad3 heterozygote (Smad3+/+, +/-) mice. They showed normal 
immune phenotypes with C57BL/6 background in a specific pathogen free environment (Fig. 1), 
indicating that R-Smads are dispensable for immune homeostasis. T cell-specific and systemic deletion of 
Smad2 ameliorated, whereas Smad3 heterozygosity exacerbated CIA (Fig. 2a and 3a). Because both 
systemic and T cell-specific deletion of Smad2 showed the same phenotype (Fig. 3a and 3b), I used 
Cd4Cre;Smad2+/+,+/fl. fl/fl mice for further study. Cd4Cre;Smad2fl/fl mice showed significant amelioration 
in joint lesions, whereas Smad3+/- mice showed proliferative detritic synovitis with mononuclear cell 
infiltration and joint destruction (Fig. 2b, upper). Evaluation of proteoglycan and mucopolysaccharide of 
cartilage by staining with toluidine blue and Safranin O showed the significant maintenance of cartilages 
in Cd4Cre;Smad2fl/fl mice and marked destruction of cartilages in Smad3+/- mice (Fig. 2b, lower). 
Accumulation of CD4+, RORγt+, and IL-17A+ cells in the joint lesions was ameliorated in 
Cd4Cre;Smad2fl/fl mice, whereas it was exacerbated in Smad3+/- mice (Fig. 4-6). Consistent with the joint 
lesions, IL-17A+, RORγt+, IL-17A+TNF-α+ and IL-17A+RORγt+ CD4+ T cells decreased in the draining 
lymph nodes of the arthritic joints of Cd4Cre;Smad2fl/fl mice and Mx-1Cre;Smad2fl/fl mice, whereas they 
increased significantly in those of Smad3+/- mice (Fig. 2c and 3b). Smad genotypes did not affect other 
effector T cell subsets, such as IL-6+CD4+, TNF-α+CD4+, Th1 (T-bet+IFN-γ+CD4+), natural and inducible 
Treg cells (CD103-Foxp3+CD4+, CD103+Foxp3+CD4+), naïve and memory CD4+ and CD8+ T cells 
(CD44lowCD62Lhigh, CD44highCD62Llow) in the draining lymph nodes of the arthritic joints (Fig. 7). Thus, 
Smad2 and Smad3 have the opposing roles in Th17 differentiation in the pathogenesis of CIA. 
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Figure 1 Smad2 and Smad3 are not essential for T cell homeostasis.  
Numbers of naïve/memory CD4+ T cells, naïve/memory CD8+ T cells, and Foxp3+ Tregs in spleens and 
superficial lymphnodes from (a) Cd4Cre;Smad2+/+, +/fl, fl/fl mice, (b) Mx-1Cre;Smad2+/+, fl/fl mice, and (c) 
Smad3+/+, +/-, -/- mice (12-16 weeks of age, Cd4Cre;Smad2 and Smad3, n = 10/genotype, Mx-1Cre;Smad2, 
n = 5 genotype). Data are from one experiment representative of seven independent experiments. Data are 
mean + s.d.  
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Figure 2 Opposing effects of Smad2 and Smad3 on Th17 response in CIA.  
Cd4Cre;Smad2+/+, +/fl, fl/fl and Smad3+/+, +/- mice were immunized with type II collagen emulsified in 
complete Freund adjuvant twice in 3 weeks interval to induce CIA. (a) CIA scoring courses of 
Cd4Cre;Smad2+/+, Cd4Cre;Smad2+/fl, Cd4Cre;Smad2 fl/fl mice (left, n = 11/Cd4Cre;Smad2 genotype) and 
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Smad3+/+,  Smad3+/- mice (right, n = 13/Smad3 genotype) with P values (two-way ANOVA test). (b) 
Pathological analyses of the joint sections (haematoxylin and eosin: HE, magnification, ×40, scale bar: 
100 µm, toluidine blue and safranin O, magnification, ×200, scale bar: 50 µm). (c) Flow cytometry 
analyses of IL-17A+TNF-α+ CD4+ T cells and RORγt+IL-17A+ CD4+ T cells in the draining lymph nodes 
of Cd4Cre;Smad2+/+,+/fl, fl/fl (n = 20/Cd4Cre;Smad2 genotype) and Smad3+/+,+/- mice  (n = 15/Smad3 
genotype) on day 14 after second immunization. Graphs show the percentages and cell numbers of 
IL-17A+, RORγt+, IL-17A+TNF-α+ and IL-17A+RORγt+ in CD4+ gates in the draining lymph nodes. Data 
are from one experiment representative of seven (a, b), four (c, Cd4Cre;Smad2) or three (c, Smad3) 
independent experiments. Graphs show mean + s.d. with P values (unpaired Student’s t-test). 
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Figure 3 Inducible systemic disruption of the Smad2 gene ameliorates CIA.  
(a) CIA scoring courses of Mx-1Cre;Smad2+/+, +/fl, fl/fl mice (n = 10/genotype) are shown. Dot plots and 
graphs of the proportions and numbers of IL-17A+RORγt+CD4+ draining lymph node cells from 
Mx-1Cre;Smad2+/+,fl/fl mice are shown. (b) Dot plots and proportions of IL-6+TNF-α+CD4+, 
T-bet+IFN-γ+CD4+, CD25+Foxp3+CD4+, CD62LhighCD44low, CD62LlowCD44high CD4+ T cells and 
CD44low,CD44high CD8+ T cells in the draining lymph nodes from Mx-1Cre;Smad2+/+,fl/fl mice are shown. 
Data are from one experiment representative of two independent experiments. Data are mean + s.d. with 
P values (two-way ANOVA test). 
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Figure 4 Accumulation of CD4+ cells in the joint lesions was ameliorated in Cd4Cre;Smad2fl/fl mice, 
whereas it was exacerbated in Smad3+/- mice.  
Immunohistochemistry staining of CD4+ in the joint sections (magnification, ×400, scale bars: 50 µm). Data are from 
one experiment representative of two independent experiments (Cd4Cre;Smad2 and Smad3, n = 10/genotype). 
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Figure 5 Accumulation of RORγt+ cells in the joint lesions was ameliorated in Cd4Cre;Smad2fl/fl 
mice, whereas it was exacerbated in Smad3+/- mice.  
Immunohistochemistry staining of RORγt+ in the joint sections (magnification, ×400, scale bars: 50 µm). Data are 
from one experiment representative of two independent experiments (Cd4Cre;Smad2 and Smad3, n = 10/genotype).  
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Figure 6 Accumulation of IL-17A+ cells in the joint lesions was ameliorated in Cd4Cre;Smad2fl/fl 
mice, whereas it was exacerbated in Smad3+/- mice.  
Immunohistochemistry staining of IL-17A+ in the joint sections (magnification, ×400, scale bars: 50 µm). Data are 
from one experiment representative of two independent experiments (Cd4Cre;Smad2 and Smad3, n = 10/genotype).  
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Figure 7 Disruption of Smad2 or Smad3 has no effect on effector T cell subsets except Th17 in CIA.  
Flow cytometry analyses of T cells in the draining lymph nodes of the arthritic joints from 
Cd4Cre;Smad2+/+, +/fl, fl/fl mice and Smad3+/+, +/- mice (a) IL-6+TNF-α+ in CD4+ gates, (b) T-bet+IFN-γ+ in 
CD4+ gates, (c) CD25+Foxp3+ in CD4+ gates, CD103-CD25+Foxp3+ in CD4+ gates, CD103+CD25+Foxp3+ 
in CD4+ gates, (d) CD62LhighCD44low, CD62LlowCD44high CD4+ T cells and CD44low, CD44high CD8+ T 
cells (n = 10/genotype). Data are from one experiment representative of four (Cd4Cre;Smad2+/+, fl/fl, n = 
20/genotype, Cd4Cre;Smad+/fl, n = 15) or three (Smad3, n = 15/genotype) independent experiments. Data 
are mean + s.d.  
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Opposing functions of Smad2 and Smad3 as STAT3 cofactors 
 IL-6 is the main arthritogenic cytokine and TGF-β is produced and activated in the inflammatory lesions 
(Li MO et al, 2006; Travis MA et al, 2014; Kimura A et al, 2010). Because IL-6 and TGF-β are the 
pivotal cytokines to induce Th17 differentiation, I cultured Smad2-/- or Smad3-/- CD4+ T cells under 
Th17-polarizing condition with IL-6 and TGF-β (Veldhoen M et al, 2006) to examine the mechanisms 
whereby R-Smads regulate Th17 differentiation. Expression levels of protein and mRNA of RORγt and 
IL-17A decreased in Smad2-/- CD4+ T cells, whereas those increased in Smad3-/- CD4+ T cells (Fig. 8a,b). 
The mRNA levels of Th17-inducing genes (Batf, Il23r, Il6, Il6ra, Il21, and Il21r) and Th17-suppressing 
genes (Il2, Il2ra, Tbet, and Eomesodermin) were unaffected in both Smad2-/- and Smad3-/- CD4+ T cells 
(Fig. 9), suggesting that R-Smads regulate Th17 differentiation by specifically targeting the Rorc and 
Il17a genes. Because IL-6 or TGF-β alone has little effect on Th17 differentiation (Veldhoen M et al, 
2006) and STAT3-mediated IL-6 signaling is crucial for Th17 differentiation (Massague J et al, 2005), I 
examined whether R-Smads regulate STAT3-induced transcription of RORγt and IL-17A in CD4+ T cells 
cultured under Th17-polarizing condition by promoter assays with the luciferase reporters spanning 2 
kilobase upstream of the first exons of the Rorc and Il17a genes (Fig. 8c). STAT3 or Smad2 alone induced 
their promoter activities, whereas Smad3 alone had no effect. Smad2 further enhanced, whereas Smad3 
suppressed STAT3-induced reporter activation. Co-transfection of Smad4 with R-Smads and STAT3 did 
not show the additive effects. I next determined the binding of R-Smads to the proximal promoter regions 
of the Rorc and Il17a genes in Th17 cells by chromatin immunoprecipitation (ChIP) using the primers to 
detect the DNA-binding sequences of Smads and STAT3 (Heldin CH et al, 2012; Durant L et al, 2010; 
Yang XP et al, 2011). Smad2 and Smad3 were bound to the same sites in the Rorc promoter, whereas they 
were bound to the distinct sites in the Il17a promoter (Fig. 8d). Active promoters are characterized by 
histone acetylation and trimethylation of H3K4, whereas repressed inactive chromatin is marked by 
methylation of H3K27 and H3K9 (Gaarenstroom T et al, 2014). Smad2-binding sites in the Il17a 
promoter showed higher acetylation of histone H3 and trimethylation of histone H3K4, which correlate 
with transcriptionally active chromatin (Fig. 10a). By contrast, Smad3-binding sites in the Il17a promoter 
showed higher trimethylation of histone H3K27, which correlate with transcriptionally inactive chromatin 
(Fig. 10b). These data suggest that Smad2 and Smad3 have the opposing roles in STAT3-induced 
transcription of the Rorc and Il17a genes. 
 I next examined whether STAT3 was necessary for R-Smads to bind to these sites by STAT3 
knockdown using siRNA in Th17 cells (Fig. 11). STAT3 knockdown completely abolished the binding of 
R-Smads to these sites (Fig. 8e). I then confirmed whether R-Smads are sufficient for STAT3 to bind to 
these sites using Smad2-/- and Smad3-/- Th17 cells. STAT3 bound to the Smad2/3-binding sites in the Rorc 
promoter or the Smad2-binding site in the Il17a promoter (Fig. 8f,g, white bars). Deficiency of Smad2 or 
Smad3 prevented STAT3 from binding to these sites (Fig. 8f,g, black bars). Thus, R-Smads and STAT3 
are mutually required to bind to the proximal promoters of the Rorc and Il17a genes. Taken together, 
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Smad2 functions as a transcription coactivator, whereas Smad3 functions as a transcription corepressor of 
STAT3 in Th17 differentiation. 
 
Figure 8 Opposing roles of Smad2 and Smad3 in STAT3-induced Th17 differentiation.  
Purified CD4+ T cells were activated under Th17-polarizing condition for 3 days. (a) Flow cytometry 
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analyses of IL-17A and RORγt in Smad2+/+,+/-, -/- and Smad3+/+,+/-, -/- CD4+ T cells. (b) Quantitative 
RT-PCR analysis of the Il17a and Rorc mRNA in Smad2+/+, -/- and Smad3+/+, -/- Th17 cells (n = 7). (c) 
Effects of Smads on STAT3-induced activation of the Rorc promoter and the Il17a promoter constructs 
transfected in Th17 cells were analyzed by luciferase assay. (d) Binding of Smad2 and Smad3 to the 
proximal promoter regions of the Rorc gene and the Il17a gene in Th17 cells was determined by ChIP. (e) 
Requirement of STAT3 for the binding of Smad2 and Smad3 to the proximal promoter regions of the 
Rorc gene and the Il17a gene was determined by ChIP using STAT3 knockdown Th17 cells. 
Requirement of Smad2 and Smad3 for the binding of STAT3 to the proximal promoter regions of the 
Rorc gene and the Il17a gene was determined by ChIP using (f) Smad2-/- or (g) Smad3-/- Th17 cells. ChIP 
data are shown as differential occupancy fold changes. Data are from one experiment representative of 
seven (a, d), three (c), two (e) or five (f, g) independent experiments or pooled from seven experiments 
(b). Each experiment (a-g) was performed in triplicate (n = 3). Data are mean + s.d. or mean + s.d. with P 
values (b, unpaired Student’s t-test). 
 
 
Figure 9 Disruption of Smad2 or Smad3 has no effect on Th17-related genes except the Rorc and 
Il17a genes.  
Quantitative RT-PCR analysis of Batf, Il23r, Il6, Il6ra, Il21, Il21r, Il2, Il2ra, Tbet, Eomes to Gapdh in 
Smad2+/+, -/- and Smad3+/+,  -/- Th17 cells. Data are pooled from three independent experiments. Each 
experiment was performed in triplicate (n = 3). Data are mean + s.d.  
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Figure 10 Smad2 binding sites are associated with active epigenetic marks, whereas Smad3 binding 
sites are associated with inactive epigenetic marks in the Rorc and Il17a promoter regions.  
ChIP analysis of Th17 cells with antibodies against (a) acetylated histone H3 (H3Ac), trimethylated histone H3 
Lys4 (H3K4me3), and (b) trimethylated histone H3 Lys 27 (H3K27me3). Data are from one experiment 
representative of two independent experiments. Each experiment was performed in triplicate (n = 3). Data are 
mean + s.d.   
 
 
 
 
 
 
 
 
 
Figure 11 Knockdown of the Stat3 gene using STAT3 siRNA in Th17 cells.  
Stat3 mRNA levels in Th17 cells transduced with the controls or STAT3 siRNA were confirmed by 
quantitative RT-PCR. Flow cytometry analyses of IL-17A+RORγt+ in CD4+ gates transduced with pcDNA, 
control siRNA or STAT3 siRNA in Th17-polarizing condition. Data are from one experiment representative of 
two independent experiments. Each experiment was performed in triplicate (n = 3). Data are mean + s.d. 
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Linker-phosphorylated Smad2 induces Th17 differentiation 
 I investigated the mechanism how Smad2 functions as a transcription coactivator of STAT3. Proximity 
ligation assays (PLA) confirmed the endogenous close proximity between Smad2 and STAT3 in Th17 
cells (Fig. 12a, left). I found that pSmad2L had close proximity with STAT3 in Th17 cells (Fig. 12a, 
right). By contrast, C-terminally phosphorylated Smad2 (pSmad2C) did not show close proximity with 
STAT3 (Fig. 12a, middle). PLA and immunoprecipitation of 293T cells transfected with the various 
deletion mutants of Smad2 showed that Smad2 linker deletion mutants (MH1 and MH2) (Kawabata M et 
al, 1999). failed to bind with STAT3 (Fig. 12b and 13a). Transfection of the linker variants of Smad2 
showed that the mutant of the linker serine residue 255 to alanine: Smad2 (S255A) (Sekimoto G et al, 
2007) failed to bind with STAT3 (Fig. 12c and 13b). Luciferase reporter assays showed that Smad2 
(S255A) failed to enhance STAT3-induced activation of the Rorc and Il17 promoters (Fig. 12d). 
Overexpression of Smad2 (S255A) in CD4+ T cells cultured under Th17-polarizing condition impaired 
Th17 differentiation (Fig. 12e). Therefore, pSmad2L (Ser255) is essential for Th17 differentiation. 
 The histone acetyl-transferase p300 is a crucial transcription coactivator of Smads (Massague J et al, 
2005; Janknecht R et al, 1998). PLA showed that STAT3 and pSmad2L, but not pSmad2C, had the close 
proximity with p300 in Th17 cells (Fig. 12f). Luciferase reporter assays confirmed that p300 further 
enhanced Smad2/STAT3-induced activation of the Rorc and Il17 promoters in 293T cells (Fig. 12g). 
Smad2, STAT3, and p300 bound to the same sites in the proximal promoters of the Rorc and Il17a genes 
in TH17 cells (Fig. 12h). Thus, pSmad2L (Ser255) forms complex with p300 and STAT3 to bind to the 
proximal promoter of the Rorc and Il17a genes. 
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Figure 12 Linker-phosphorylated Smad2 (S255)-STAT3-p300 complex transactivates the Rorc and 
Il17a.  
Interactions of endogenous proteins in Th17 cells and exogenous proteins in 293T cells were determined 
by proximity ligation assay (PLA). PLA signals (a-c, f) were quantified using BlobFinder software (scale 
bars: 10 µm, nucleus: black, cytoplasm: white, n = 10 fields). (a) Endogenous interaction between Smad2 
and STAT3 in Th17 cells. (b) Effects of truncated mutations in Smad2 on the interaction with STAT3 in 
293T cells. (c) Effects of linker domain variations in Smad2 on the interaction with STAT3 in 293T cells. 
(d) Effects of Smad2 (S255A) on STAT3-induced activation of the Rorc promoter and the Il17a promoter 
constructs transfected in Th17 cells were analyzed by luciferase assay. (e) Flow cytometry analyses of 
IL-17A+RORγt+CD4+ T cells transduced with the indicated DNA constructs using Nucleofector (n = 2). 
(f) Endogenous interactions between p300 and Smad2 or STAT3 in Th17 cells were determined by PLA. 
(g) Effects of p300 on Smad2/STAT3-induced activation of the Rorc promoter (white) and the Il17a 
promoter (black) constructs transfected in 293T cells were analyzed by luciferase assay. (h) Binding of 
Smad2 (white) and p300 (black) to the proximal promoter regions of the Rorc gene and the Il17a gene in 
Th17 cells was determined by ChIP. ChIP data are shown as differential occupancy fold changes. Data are 
from one experiment representative of six (a), three (b-d) or two (e-h) independent experiments. Each 
experiment (d, g, h) was performed in triplicate (n = 3). Data are mean + s.d. 
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Figure 13 Linker-phosphorylated Smad2 at S255 interacts with STAT3.  
Interactions of exogenous Smad2 proteins and STAT3 protein in 293T cells were determined by 
immunoprecipitation. (a) Effects of truncated mutations in Smad2 on the interaction with STAT3 in 293T 
cells. (b) Effects of linker domain variations in Smad2 on the interaction with STAT3 in 293T cells. Data 
are from one experiment representative of three independent experiments. 
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Unphosphorylated Smad3 suppresses Th17 differentiation 
 I investigated the mechanism how Smad3 functions as a transcription corepressor of STAT3. PLA 
confirmed the endogenous close proximity between Smad3 and STAT3 in Th17 cells (Fig. 14a). Unlike 
R-Smads, Smad4 did not interact with STAT3 (Fig. 14a). Although STAT5 and STAT3 oppositely 
regulate Th17 differentiation by binding the multiple common sites across the locus encoding IL-17 
(Yang XP et al, 2011), neither Smad2 nor Smad3 interacted with STAT5 (Fig. 15). Furthermore, 
interactions between Smad2/3 and STAT3 were more significant than the established interaction controls: 
pSmad2/3C-Smad4 (Massague J et al, 2005; Heldin CH et al, 2012) and Smad2/3-RORγt (Martinez GJ 
et al, 2009; Martinez GJ et al, 2010) (Fig. 16). PLA and immunoprecipitation of 293T cells transfected 
with the various deletion mutants of Smad3 showed that Smad3 MH2 deletion mutants (MH1 and 
MH1+L) (Kawabata M et al, 1999; Sekimoto G et al, 2007) failed to bind with STAT3 (Fig. 14b and 
Fig. 17). Thus, MH2 domain is required for Smad3 to bind STAT3. 
 PIAS3 belongs to the mammalian protein inhibitor of activated STAT (PIAS) protein family, which 
represses STAT3-dependent transcriptional activation by blocking the DNA-binding activity of STAT3, 
regardless of its small ubiquitin-like modifier-E3 ligase activity (Chung CD et al, 1997). Overexpression 
of Smad3, the deletion mutant lacking MH2 domain, or the C-terminal mutant in Th17 cells show that 
Smad3 MH2 domain, but not C-terminal SSXS motif, is functionally responsible for the suppression of 
Th17 differentiation (Fig. 14c). Because PIAS3 interacts with Smad3 at its C-terminal domain (Long J et 
al, 2004), I examined whether Smad3 recruits PIAS3 to repress STAT3-induced transcription of the Rorc 
and Il17a genes. PIAS3 showed the close proximity with both STAT3 and Smad3, but not with C-terminally 
phosphorylated Smad3 (pSmad3C) or Smad2 in Th17 cells (Fig. 14d). STAT3-PIAS3 interaction was 
completely abolished in Smad3-/- Th17 cells (Fig. 14e). A mutant of serine residues to alanine in Smad3 
SSXS motif, Smad3 (3S-A) was yet capable of binding with STAT3 and PIAS3 in 293T cells (Fig. 14f). 
Consistently, when co-transfected with PIAS3 in Th17 cells, Smad3 (3S-A) was able to suppress 
STAT3-induced activation of the Rorc and Il17a reporters (Fig. 14g). ChIP revealed that PIAS3 and 
Smad3, but not pSmad3C, bound to the same sites in the Rorc and Il17a promoters (Fig. 14h and Fig. 18). 
Thus, C-terminal phosphorylation is not required for Smad3 to bind with STAT3 and PIAS3. 
Overexpression of PIAS3 suppressed Th17 differentiation, whereas knockdown of PIAS3 by siRNA 
abolished the binding of Smad3 to the Rorc and Il17a promoter regions, although Th17 differentiation 
was unaltered by knockdown of PIAS3 presumably because relatively predominant binding of Smad2 
over Smad3 in the absence of PIAS3 transactivated the Rorc and Il17a genes (Fig. 19). These data 
indicate that unphosphorylated Smad3C in cooperation with PIAS3 represses STAT3-induced 
transcription of the Rorc and Il17a gene 
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Figure 14 C-terminally unphosphorylated Smad3 recruits PIAS3 to act as a transcription 
corepressor of STAT3 in Th17 differentiation.  
Interactions of endogenous proteins in Th17 cells and exogenous proteins in 293T cells were determined 
by PLA. PLA signals (a, b, d-f) were quantified using BlobFinder software (scale bars: 10 µm, nucleus: 
black, cytoplasm: white, n = 10 fields). (a) Endogenous interactions between Smad3/Smad4 and STAT3 
in Th17 cells. (b) Effects of truncated mutations in Smad3 on the interaction with STAT3 in 293T cells. 
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(c) Flow cytometry analyses of IL-17A+RORγt+CD4+ T cells transduced with the indicated DNA 
constructs using Nucleofector (n = 4). (d) Endogenous interactions between PIAS3 and 
STAT3/Smad2/Smad3 in Th17 cells. (e) Endogenous interaction between PIAS3 and STAT3 in Smad3+/+, 
-/- Th17 cells. (f) Effects of Smad3 C-terminal mutation on the interaction with STAT3 (left) or the 
interaction with PIAS3 (right) in 293T cells. (g) Effects of PIAS3, Smad3 MH2 deletion, and 
Smad3C-terminal mutation on STAT3-induced activation of the Rorc promoter and the Il17a promoter 
constructs transfected in Th17 cells were determined by luciferase assay. (h) Binding of Smad3 (white) 
and PIAS3 (black) to the Rorc and the Il17a promoter regions in Th17 cells was determined by ChIP 
(differential occupancy fold changes). A representative of six (a), three (b, f, g), four (c, d) or two (e, h) 
independent experiments is shown. Each experiment (g, h) was performed in triplicate (n = 3). Data are 
mean + s.d. or mean + s.d. with P values (e, unpaired Student’s t-test). 
 
 
 
 
 
 
 
Figure 15 TGF-β R-Smads do not interact with STAT5 in Th17 cells.  
PLA shows no close proximity between Smad2/3 and STAT5 in Th17 cells (scale bar: 10 µm). Data are 
from one experiment representative of three independent experiments.  
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Figure 16 TGF-β R-Smads show close proximity with Smad4 or RORγt in Th17 cells.  
PLA shows the endogenous close proximity between Smad2-Smad4, pSmad2C-Smad4, Smad3-Smad4, 
pSmad3C-Smad4, Smad2-RORγt, and Smad3-RORγt in Th17 cells. PLA signals were quantified using 
BlobFinder software (scale bars: 10 µm, nucleus: black, cytoplasm: white, n = 10 fields). Data are from 
one experiment representative of three independent experiments. Data are mean + s.d. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 Smad3 MH2 domain interacts with STAT3.  
Interactions of Smad3 or various Smad3 mutants and STAT3 in 293T cells were determined by 
immunoprecipitation. Data are from one experiment representative of three independent experiments. 
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Figure 18 C-terminally phosphorylated Smad3 does not bind to the PIAS3/Smad3-binding sites in 
the Rorc and Il17a proximal promoter regions in Th17 cells.  
ChIP with the antibody against pSmad3C shows that pSmad3C does not bind to the 
PIAS3/Smad3-binding sites in the Rorc and Il17a proximal promoter regions of Th17 cells. Data are from 
one experiment representative of two independent experiments. Each experiment was performed in 
triplicate (n = 3). Data are mean + s.d.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 PIAS3 is required for Smad3 to bind to the Rorc and the Il17a promoter regions.  
(a) PIAS3 mRNA levels in Th17 cells transduced with the control siRNA or PIAS3 siRNA were 
confirmed by quantitative RT-PCR. (b) Flow cytometry analyses of IL-17A+RORγt+CD4+ T cells 
transduced with control siRNA, PIAS3 siRNA or PIAS3 in Th17-polarizing condition. (c) ChIP analysis 
of Th17 cells transduced with control siRNA or PIAS3 siRNA with the antibodies against Smad2 and 
Smad3. One experiment was performed in triplicate (n = 3). Data are mean + s.d.  
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ERK phosphorylates Smad2 linker in Th17 differentiation 
 Previous studies have paid attention to C-terminal phosphorylation of R-Smads as TGF-β signaling 
mediators in Th17 differentiation (Xiao S et al, 2008; Martinez GJ et al, 2009; Lu L et al, 2010; Martinez 
GJ et al, 2010; Malhotra N et al, 2010; Takimoto T et al, 2010). However, pSmad2L (Ser255) and 
unphosphorylated Smad3 are not involved in the canonical C-terminally phosphorylated 
R-Smad/Smad4-mediated TGF-β signaling. Three clustered serine residues in the linker regions of Smad2 
(Ser245/250/255) are the phosphorylation sites for MAPKs (ERK, JNK, and p38) (Kretzschmar M et al, 
1999; Massague J et al, 2003; Wrighton KH et al, 2009; Heldin CH et al, 2012; Matsuzaki K et al, 2013). 
Because MAPKs are shared by TGF-β, IL-6, and TCR, I sought to identify the MAPK responsible for 
Smad2 linker phosphorylation in Th17 differentiation.  
 Signal intensities of TGF-β, IL-6, and TCR have been reported to correlate with the extent of Th17 
differentiation (Veldhoen M et al, 2006; Manel N et al, 2008; Hirahara K et al, 2010). Therefore, I treated 
CD4+ T cells under Th17-polarizing condition with various concentrations of TGF-β, IL-6, and anti-CD3 
antibody. I confirmed that higher doses of TGF-β1, anti-CD3 antibody, and IL-6 induced more Th17 
differentiation (Fig. 20a, 21a and 22a). Percentages of IL-17A+RORγt+CD4+ T cells were directly 
proportional to phosphorylation of Smad2L (Fig. 20b, 21b and 22b) and ERK, but not to phosphorylation 
of JNK or p38 (Fig. 20c, 23 and 24).  
 To confirm whether TβRI-mediated phosphorylation of Smad2L is required for Th17 differentiation, I 
treated CD4+ T cells under Th17-polarizing condition with specific inhibitors against TβRI (Yoon JH et al, 
2013) at the doses that maintain cell viability (Fig. 25). A potent selective ATP-competitive inhibitor of 
TβRI kinase (activin receptor-like kinase5: ALK5), EW-7197 (Yoon JH et al, 2013; Jin CH et al, 2014) 
completely suppressed Th17 differentiation at the dose of 0.5 mM (Fig. 20d). Treatment with EW-7197 
suppressed pSmad2L (Fig. 20e) and phosphorylation of ERK, but not phosphorylation of JNK and p38 
(Fig. 20f and Fig. 26). One of the prototype ALK5 inhibitors, SB-505124 inhibits TGF-β-induced 
activation of MAPKs without altering ALK5-independent MAP kinase pathways (DaCosta Byfield S et al, 
2004). A more highly selective ALK5 inhibitor, EW-7197 does not directly inhibit MEK1 and ERK1 (Jin 
CH et al, 2014). Therefore, inhibitory effect of EW-7197 on ERK phosphorylation is ALK5-specific. 
Culture media containing IL-6, IL-23, and IL-1β is sufficient to induce Th17 in the absence of TGF-β 
(Ghoreschi K et al, 2010). However, EW-7197 inhibited, whereas TGF-β1 enhanced Th17 differentiation 
along with ERK phosphorylation even in this culture condition (Fig. 27). These results suggest that 
TGF-β-TβRI signal phosphorylates ERK and pSmad2L in Th17 cells. 
 To confirm whether ERK-mediated phosphorylation of Smad2L is required for Th17 differentiation, I 
next treated CD4+ T cells under Th17-polarizing condition with specific inhibitors against MAPKs at the 
doses that maintain cell viability (Fig. 28 and 29). A MEK inhibitor: PD98059 suppressed Th17 
differentiation in a dose dependent manner (Fig. 20g and 28), whereas a JNK inhibitor: SP600125 or p38 
inhibitor: SB203580 did not affect Th17 differentiation (Fig. 29). PD98059 showed the similar effects 
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with EW-7197 on pSmad2L (Fig. 20h). Specific inhibition of MAP kinase by the corresponding inhibitor 
was confirmed (Fig. 30). Taken together, ERK-mediated Smad2 linker phosphorylation is responsible for 
Th17 differentiation and the concentrations of TGF-β, TCR, and IL-6 determine the intensities of Smad2 
linker phosphorylation and the extent of Th17 differentiation. 
Figure 20 ERK induces Smad2 linker phosphorylation that facilitates Th17 differentiation.  
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Purified CD4+ T cells were activated under Th17-polarizing condition with the indicated doses of TGF-β1 
and plate-coated anti-CD3 antibody, or small molecule inhibitors (EW-7197: ALK5 inhibitor, PD98059: 
MEK inhibitor) for 3 days. (a) Flow cytometry analyses of IL-17A+RORγt+CD4+ T cells treated with 
TGF-β1 and plate-coated anti-CD3 antibody. (b) Endogenous expression of pSmad2L in Th17 cells 
treated with TGF-β1 and plate-coated anti-CD3 antibody was determined by PLA. (c) Flow cytometry 
analyses of phospho-ERK in Th17 cells treated with TGF-β1 and plate-coated anti-CD3 antibody. (d) 
Flow cytometry analyses of IL-17A+RORγt+CD4+ T cells treated with EW-7197. (e) Endogenous 
expression of pSmad2L in Th17 cells treated with EW-7197 was determined by PLA. (f) Flow cytometry 
analyses of phospho-ERK in TH17 cells treated with EW-7197. (g) Flow cytometry analyses of 
IL-17A+RORγt+CD4+ T cells treated with PD98059. (h) Endogenous expression of pSmad2L in Th17 
cells treated with PD98059 was determined by PLA. The values of mean fluorescence intensity (MFI) are 
shown in histograms. PLA signals (b, e, h) were quantified using BlobFinder software (scale bars: 10 µm, 
nucleus: black, cytoplasm: white, n = 10 fields). Data are representative of two (a-h) independent 
experiments. Data are mean + s.d. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 Strength of TGF-β and TCR signals correlate with Th17 differentiation and pSmad2L.  
Purified CD4+ T cells were activated under Th17-polarizing condition with the indicated doses of TGF-β 
and plate-coated anti-CD3 for 3 days. (a) Percentages of IL-17A+RORγt+CD4+ T cells determined by 
flow cytometry. (b) Expression of pSmad2L in CD4+ T cells determined by PLA. PLA signals were 
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quantified using BlobFinder software (nucleus: black, cytoplasm: white, n = 10 fields). Data are from one 
experiment representative of two independent experiments. Data are mean + s.d. 
Figure 22 IL-6 doses correlate with Th17 differentiation.  
Purified CD4+ T cells were activated under Th17-polarizing condition with the indicated doses of IL-6 for 
3 days. (a) Flow cytometry analyses of IL-17A+RORγt+CD4+ T cells. (b) Expression of pSmad2L in 
CD4+ T cells determined by PLA. PLA signals were quantified using BlobFinder software (scale bars: 10 
µm, nucleus: black, cytoplasm: white, n = 10 fields). Data are from one experiment representative of two 
independent experiments. Data are mean + s.d. 
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Figure 23 Strength of TGF-β and TCR signals correlate with ERK phosphorylation.  
Purified CD4+ T cells were activated under Th17-polarizing condition with the indicated doses of TGF-β, 
and plate-coated anti-CD3 for 3 days. Flow cytometry analyses of phospho-ERK, phospho-JNK, and 
phospho-p38 in RORγt+CD4+ gate. Graphs show mean fluorescence intensity (MFI). Data are from one 
experiment representative of two independent experiments. 
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Figure 24 High doses IL-6 enhance ERK phosphorylation.  
Purified CD4+ T cells were activated under Th17-polarizing condition with the indicated doses of IL-6 for 
3 days. Flow cytometry analyses of phospho-ERK, phospho-JNK, and phospho-p38 in RORγt+CD4+ gate. 
Graphs show mean fluorescence intensity (MFI). Data are from one experiment representative of two 
independent experiments. 
Figure 25 Viability and Th17 differentiation of CD4+ T cells treated with ALK5 inhibitor, 
EW-7197.  
Purified CD4+ T cells were activated under Th17-polarizing condition with the indicated doses of 
EW-7197 for 3 days. Flow cytometry analyses of FSC/SSC and IL-17A+RORγt+CD4+ T cells. Data are 
from one experiment representative of two independent experiments.  
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Figure 26 ALK5 inhibitor, EW-7197 suppresses ERK phosphorylation, but not phosphorylation of 
JNK and p38.  
Purified CD4+ T cells were activated under Th17-polarizing condition with the indicated doses of an 
ALK5 inhibitor: EW-7197 for 3 days. Flow cytometry analyses of phospho-ERK, phospho-JNK, and 
phospho-p38 in RORγt+CD4+ gate. Graphs show mean fluorescence intensity (MFI). Data are from one 
experiment representative of two independent experiments. 
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Figure 27 TGF-β enhances, whereas EW-7197 suppresses ERK phosphorylation and Th17 
differentiation induced by IL-6, IL-23 and IL-1β.  
Purified CD4+ T cells were activated under Th17-polarizing condition with IL-6, IL-23, and IL-1β in the 
presence or absence of TGF-β1 (1 ng ml-1) or EW-7197 (0.5 mM) for 3 days. (a) Flow cytometry 
analyses of IL-17A+RORγt+CD4+ T cells. The graph shows the percentages of IL-17A+RORγt+ cells in 
CD4+ gates are shown. (b) Flowcytometry analyses of phospho-ERK, phospho-JNK, and phospho-p38 in 
RORγt+CD4+ gate. Graphs show mean fluorescence intensity (MFI). Data are from one experiment 
representative of two independent experiments. 
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Figure 28 Viability and Th17 differentiation of CD4+ T cells treated with MEK inhibitor, PD98059.  
Purified CD4+ T cells were activated under Th17-polarizing condition with the indicated doses of 
PD98059 for 3 days. Flow cytometry analyses of FSC/SSC and IL-17A+RORγt+CD4+ T cells. 
Percentages of positive cell populations are shown. Data are from one experiment representative of two 
independent experiments.  
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Figure 29 Inhibitors of JNK and p38 do not suppress Th17 differentiation.  
Purified CD4+ T cells were activated under Th17-polarizing condition with the indicated doses of (a) a 
JNK inhibitor: SP600125 or (b) p38 inhibitor: SB203580 for 3 days. Flow cytometry analyses of 
FSC/SSCand IL-17A+RORγt+CD4+ T cells. Data are from one experiment representative of two 
independent experiments. 
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Figure 30 Specificity of MAPK inhibitors.  
Purified CD4+ T cells were activated under Th17-polarizing condition with the indicated doses of MAPK 
inhibitors (PD98059, SP600125, and SB203580) for 3 days. Flow cytometry analyses of phospho-ERK, 
phospho-JNK, and phospho-p38 in RORγt+CD4+ gate. Graphs show mean fluorescence intensity (MFI). 
Data are from one experiment representative of two independent experiments. 
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R-Smad-STAT3 interaction balances Th17 differentiation 
 I next examined the effects of intensities and inhibitions of TGF-β/IL-6/TCR signals on the interactions 
of STAT3 with pSmad2L or unphosphorylated Smad3C in Th17 cells. Higher doses of TGF-β1, IL-6, and 
anti-CD3 antibody significantly upregulated pSmad2L-STAT3 interactions with little changes in 
Smad3-STAT3 interactions (Fig. 31a,b and 32). By contrast, treatments with EW-7197 or PD98059 
significantly downregulated pSmad2L-STAT3 interactions (Fig. 31c,e), whereas upregulated 
Smad3-STAT3 interactions (Fig. 31d,f). Interactions of pSmad2L and STAT3 were directly proportional, 
whereas interactions of unphosphorylated Smad3C and STAT3 were inversely proportional to Th17 
differentiation of EW-7197- or PD98059-treated CD4+ T cells (Fig. 20d,g and Fig. 31c-f). These data 
suggest that the balances between STAT3-interacting pSmad2L and STAT3-interacting unphosphorylated  
Smad3C determine the extent of Th17 differentiation.   
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Figure 31 R-Smad-STAT3 interaction balances correlate with Th17 differentiation.  
Purified CD4+ T cells were activated under Th17-polarizing condition with the indicated doses of TGF-β1 
and plate-coated anti-CD3 antibody, or small molecule inhibitors (EW-7197: ALK5 inhibitor, PD98059: 
MEK inhibitor) for 3 days. Interactions of endogenous proteins in Th17 cells were determined by PLA. 
PLA signals (a-f) were quantified using BlobFinder software (scale bars: 10 µm, nucleus: black, 
cytoplasm: white, n = 10 fields). (a) pSmad2L and STAT3, (b) Smad3 and STAT3 in Th17 cells treated 
with the indicated doses of TGF-β1 and plate-coated anti-CD3 antibody. (c) pSmad2L and STAT3, (d) 
Smad3 and STAT3 in Th17 cells treated with the indicated doses of EW-7197. (e) pSmad2L and STAT3, 
(f) Smad3 and STAT3 in Th17 cells treated with the indicated doses of PD98059. Data are representative 
of two independent experiments. Data are mean + s.d.  
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Figure 32. Higher doses of (a) TGF-β1, anti-CD3 antibody, and (b) IL-6 upregulated 
pSmad2L-STAT3 interaction in the nuclei with miniscule changes in Smad3-STAT3 interaction. 
Expression of pSmad2L-STAT3 and Smad3-STAT3 was quantified by PLA. PLA signals were quantified 
using BlobFinder software (scale bars: 10 µm, nucleus: black, cytoplasm: white, n = 10 fields). Data are 
from one experiment representative of two independent experiments. Data are mean + s.d. 
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Summary 
TGF-β/IL-6/TCR-pERK-pSmad2L (Ser255) axis is the positive regulator, whereas unphosphorylated 
Smad3C-PIAS3 complex is the negative regulator of STAT3-induced transcriptional processes for Th17 
differentiation (Fig. 33). 
 
 
Figure 33 TGF-β R-Smads: Smad2 and Smad3 oppositely regulate Th17 differentiation as 
transcription cofactors of STAT3.  
ERK-phosphorylated Smad2L (S255)/STAT3/p300 activates, whereas unphosphorylated 
Smad3C/STAT3/PIAS3 represses the transcription of the Rorc and Il17a genes. 
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Discussion  
 I discovered that Smad2 and Smad3 oppositely regulated STAT3-induced Th17 differentiation through 
the novel direct signaling networks. Transmodulation between the SMAD and STAT signaling pathways 
balances the interplay between TGF-β and various cytokines. Indirect cross-talk between SMAD and 
STAT was first reported as the inhibition of Smad3/4-mediated TGF-β signaling by 
Jak1-STAT1-mediated IFN-γ signaling via induction of the inhibitory Smad, Smad7, which prevents 
TβRI-induced C-terminal phosphorylation of Smad3 (Ulloa L et al, 1999). Direct cross-talk between 
SMAD and STAT was discovered as the synergistic signaling of leukemia inhibitory factor and bone 
morphogenic protein-2, one of the TGF-β superfamily cytokines, via STAT3-Smad1 complex bridged by 
p300 in fetal neural cells (Nakashima K et al, 1999). Direct cross-talk between Smad3 and STAT3 was 
reported as the augmentation of IL-6-STAT3-mediated transactivation by TGF-β via interaction of 
STAT3-pSmad3C complex bridged by p300 in hepatoma cells (Janknecht R et al, 1998; Yang XP et al, 
2011). This study clarified the mechanisms whereby R-Smads-STAT3 networks modulate Th17 
differentiation; pSmad2L (Ser255) serves as STAT3 coactivator in combination with p300, a coactivator 
of various transcription factors including both Smads and STAT3, whereas unphosphorylated Smad3C 
serves as STAT3 corepressor in combination with PIAS3, a negative regulator of STAT3-induced 
transcription (Chung CD et al, 1997). The preceding reports and my findings indicate that SMAD-STAT 
signaling networks are highly cell-type-specific and context-dependent. Because of the relatively low 
DNA binding affinity of Smad3 and lack of DNA-binding ability of Smad2, they interact with a wide 
variety of DNA-binding proteins to co-regulate the target genes. Recently, genome-wide transcriptome 
analyses have elucidated the diverse regulatory networks of Smad2/3 with cell-type-specific master 
transcription factors and/or DNA-binding cofactors in variety of cells (Morikawa M et al, 2013). The 
thorough iterative approach to delineate the Th17 global transcriptional regulatory network shows that 
STAT3 works as one of the key activators of the initial transcriptional program, RORγt works as an 
expression modulator, and Smad3 is the negative regulators (Ciofani M et al, 2012). It is noteworthy that 
a histone demethylase, JMJD3 (KDM6B) regulates the expression of numerous targets of RORγt and 
STAT3 (Ciofani M et al, 2012) because JMJD3 causes a loss of the H3K27me3 repressive epigenetic 
mark by interacting with R-Smads at their target sites (Morikawa M et al, 2013). Therefore, it is possible 
that Smad2 may interact with JMJD3 to induce active chromatin state for Th17 regulation in the same 
manner with Nodal-Smad2/3 signaling in embryonic development (Dahle O et al, 2010) (Fig. 10). Further 
studies are required to elucidate the details of divergent context-dependent SMAD-STAT signaling 
networks implicated by genome-wide transcriptome analyses. 
 I further uncovered the novel roles of R-Smads with noncanonical phosphorylation status in networking 
with STAT3: linker phosphorylated Smad2 as a STAT3 coactivator and unphosphorylated Smad3 as a 
STAT3 corepressor. Serine/threonine-rich R-Smad linker regions contain multiple phosphorylation sites 
by proline-directed protein kinases such as MAPKs, glycogen synthase kinase 3 (GSK3), and 
 54 
 
cyclin-dependent kinase (CDK) family (Massague J et al, 2003; Wrighton KH et al, 2009; Matsuzaki K et 
al, 2013). Linker residues Ser245/250/255, Thr220 in Smad2, and Ser204/208/213, Thr179 in Smad3 are 
the sites for phosphorylation (Wrighton KH et al, 2009; Matsuzaki K et al, 2013). Three clustered serine 
residues are preferred phosphorylation sites for ERK, JNK, and p38 in response to receptor tyrosine 
kinases and proinflammatory cytokines, whereas threonine residues are preferred phosphorylation sites 
for CDK family in response to TGF-β. TβRI possesses the intrinsic tyrosine kinase activity to directly 
induce activation of MAPK pathways and subsequent phosphorylation of R-Smad linker residues in 
addition to the serine/threonine kinase activity to phosphorylate R-Smads in their conserved C-terminal 
SSXS motif (Wrighton KH et al, 2009; Matsuzaki K et al, 2013). Mitogens and hyperactive Ras induce 
ERK-mediated linker phosphorylation of Smad2 at Ser245/250/255/Thr220 and Smad3 at 
Ser204/208/Thr179 (Massague J et al, 2003; Massague J et al, 2012). Therefore, roles of R-Smad linker 
phosphorylation in carcinogenesis have been investigated intensively family (Massague J et al, 2003; 
Wrighton KH et al, 2009; Matsuzaki K et al, 2013). Central role of ERK in TCR signals family (Dong C 
et al, 2002; Liu H et al, 2013) suggests the important roles of R-Smad linker phosphorylation in T cell 
signaling network. Thus far, MEKK2/3-ERK1/2 signaling has been reported to induce pSmad3L, which 
negatively regulates canonical TGF-β signaling for Th17 differentiation (Chang X et al, 2011). Because I 
found that Smad3 linker region was not involved in STAT3-induced Th17 differentiation (Fig. 14b), the 
mechanisms how pSmad3L regulates Th17 differentiation are independent of STAT3. By contrast to 
phosphorylated Smads, very little has been known about physiological functions of unphosphorylated 
R-Smads. It has been reported that PIAS3 enhances TGF-β-induced transcriptional activity of C-terminally 
phosphorylated Smad3 by recruiting p300 and CBP in COS cells and 293T cells (Long J et al, 2004). By 
contrast, I discovered that unphosphorylated Smad3C due to less TGF-β signaling was required for 
PIAS3 to function as a corepressor of STAT3 (Chung CD et al, 1997). Recent genome-wide studies 
implicate that unphosphorylated Smad3 may bind to some cell-type specific transcription factors in both 
TGF-β-dependent and TGF-β-independent manners (Morikawa M et al, 2013; Mullen AC et al, 2011; 
Isogaya K et al, 2014). My finding shed light on as-yet-unrecognized functions of unphosphorylated 
Smad3 as a transcription cofactor. 
 The discovery of a new proinflammatory effetor T cell subset, Th17 revised the functions of TGF-β, 
which had been long considered as the most potent immunosuppressive cytokine. TGF-β has been 
identified as the requisite factor for Th17 differentiation in combination with IL-6 and other 
proinflammatory cytokines such as IL-21, IL-23, IL-1β, and TNF-α. However, as functions of TGF-β 
have been frequently described as dual, bidirectional, pleiotropic, complex, or contextual, the roles of 
TGF-β in Th17 differentiation have become controversial. Requirement of TGF-β for Th17 differentiation 
remains contradictory, indispensable or dispensable (Manel N et al, 2008; DaCosta Byfield S et al, 
2004). My results provide explanation for these conflicting reports. TGF-β ligand-independent Th17 
differentiation is possible because Smad2 linker phosphorylation could be induced by ERK signals 
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downstream of IL-6 receptor and TCR. However, significantly more effective inhibitory effect of the 
ALK5 inhibitor than that of a MEK inhibitor suggests that TβRI-pERK-pSmad2L axis is more efficient 
than non-TGF-β growth stimulatory signal-pERK-pSmad2L axis for Th17 differentiation. Nonetheless, 
the report showing the dispensability of TGF-β demonstrates that TGF-β induces significantly more Th17 
differentiation (DaCosta Byfield S et al, 2004). Likewise, my results provide explanations for the 
discrepancies in the reported roles of Smads in Th17 differentiation. My data are consistent with the 
previous reports showing that Smad2 is a positive regulator and Smad3 is a negative regulator of Th17 
differentiation although the mechanisms of actions are distinct. It has been reported that TGF-β signaling 
via Smad2 indirectly induced STAT3 phosphorylation by inducing the expression of mRNA and protein 
of IL-6Rα (Malhotra N et al, 2010), however, I could not confirm the differences in IL-6Rα mRNA 
expression in my systems (Fig. 9). It has been reported that Smad3 interacted with RORγt and decreased 
its transcriptional activity (Martinez GJ et al, 2009). I confirmed that not only Smad3 but also Smad2 
interacted with RORγt (Fig. 16). Whether RORγt forms the complex with STAT3 and R-Smads remains 
to be determined. My data also suggest that the signaling intensity balances of TCR, co-stimulation, IL-6, 
TGF-β, and other cytokines could yield the seeming dispensability of R-Smads (Lu L et al, 2010; 
Takimoto T et al, 2010) because of their opposing effects. The signaling balances between 
TβRI-PKCα-mediated C-terminal phosphorylation of R-Smads (Meisel M et al, 2013) and 
pERK-pSmad2L may be also crucial for Th17 differentiation. 
 An ALK5 inhibitor is efficacious against a mouse type II collagen antibody-induced arthritis model 
(Sakuma M et al, 2007). My results of a CIA model showed the promoting role of pSmad2L at Ser255 
and the suppressive role of unphosphorylated Smad3 in the arthritogenic Th17 differentiation.  
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Activin receptor-like kinase5 inhibition suppresses mouse 
melanoma by ubiquitin degradation of Smad4, thereby 
derepressing eomesodermin in cytotoxic T lymphocytes 
（TGF-β I 型受容体阻害は、細胞障害性 T リンパ球に発
現する Smad4 ユビキチン分解による eomesodermin 抑制
解除を誘導しマウス悪性黒色腫を抑制する）  
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Materials and Methods 
Mice  
Mice homozygous for a conditional Smad4 allele (Smad4loxp/loxp) (Kim et al, 2006) and Smad2 allele 
(Smad2 loxp/loxp) (Liu et al, 2004) were bred with Cd4Cre recombinase transgenic mice (Lee et al, 2001) for 
the selective deletion of the genes flanked by loxP targeting sequences in thymocytes at the double 
positive stage. They were backcrossed to C57BL/6 (The Jackson Laboratory) for eight generations. 
Smad3+/- mice (Yang et al, 1999) were backcrossed to C57BL/6 for two generations because the 
probability of Smad3-/- dropped to less than 1% in my facility due to the increased embryonic lethality. 
All experiments used age-matched mice. All animals were maintained in a SPF environment and used in 
experiments according to the ethical guidelines for animal experiments and the safety guidelines for gene 
manipulation experiments at University of Tsukuba, Japan, Tokyo Medical University, Japan, Gachon 
University, Korea, and Konkuk University, Korea under approved animal study protocols. 
 
B16 melanoma model and treatment with ALK5 inhibitors 
Parental B16F1 (B16) cells and B16 cells transfected with the FG12 lentiviral vector expressing green 
fluorescent protein (GFP) were cultured in DMEM media (Gibco) containing 10% heat-inactivated FBS 
(Gibco) supplemented with 1% penicillin and streptomycin. Mice (8-12 wk) were subcutaneously injected 
with GFP-expressing B16 cells (4×104/20 µl) into the left footpads or with GFP-expressing B16 cells 
(2×105/100 µl) into the left lower abdomen. Tumor size was measured by a caliper everyday. Volume was 
calculated by ([short diameter]2 × long diameter)/2 (Pedroza-Gonzalez et al, 2011). Resected tumor was 
weighed. Tumors, dLNs (left axillary, brachial, and inguinal), non-dLNs, and spleens were harvested for 
evaluation. EW-7197 (2.5 mg/kg daily) or LY-2157299 (75 mg/kg bid) dissolved in artificial gastric fluid 
formulation (vehicle; ddH2O 900 ml, conc. HCl 7 ml, NaCl 2.0g, pepsin 3.2g) was given orally by 
feeding needle to mice from 4 days after inoculation. To delete CD8+, CD4+ T cells, or NK cells, mice 
were intraperitoneally injected with LEAF purified anti-CD4 (GK1.5), anti-CD8 (53-6.7) (150 µg/mouse; 
BioLegend) or anti-asialo GM1 (20 µl/mouse ; Wako) antibody on day -4, 0, 7, and 14 of melanoma 
inoculation (day 0). Rat IgG2a κ (150 µg/mouse; BioLegend) was used as a representative control. 
 
Isolation of TILs 
Melanoma infiltrating T cells were isolated following the reported protocol (Watkins et al, 2012). Briefly, 
B16 melanoma tumors measuring up to 250 mm2 were cut into small pieces and incubated in RPMI 
medium supplemented with 5% FBS, Collagenase type I (200U/ml; Sigma-Aldrich) and DNase I (100 
µg/ml; Sigma-Aldrich) for 30 min at 37°C. Cells were enriched by density gradient centrifugation using 
Ficoll-Paque 1.084 (GE Healthcare). Enriched cells were isolated by filtering through Cell Strainers (pore 
size: 40-µm diameter) (BD Falcon). Erythrocytes were lysed using RBC Lysis Buffer (Rhoche) and cells 
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were washed in PBS containing 2% FBS (Hyclone Laboratories). Viable cells were counted by 
hemacytometer using trypan blue exclusion. 
 
Flowcytometry 
Single cell suspensions were prepared from spleens and LNs. After blocking Fc receptors by anti-mouse 
CD16/CD32, cells were stained with APC-Cy7-anti-CD4, Pacific blue-anti-CD8, PE-anti-CD19, 
APC-anti-CD11b, PE-anti-Gr-1, APC-anti-CD11c, APC-anti-DX5, and APC-anti-CD45. To measure 
cytokine production, dLN cells were stimulated with PMA (2.5 ng/ml; Sigma-Aldrich) and ionomycin 
(2.5 ng/ml; Sigma-Aldrich) with GolgiPlug (BD Pharmingen) for 1-4 h. Cells were fixed, permeabilized 
with a Cytoperm/Cytofix Kit (eBiosciences). For intracellular staining, PE-anti-T-bet, APC-anti-Eomes, 
PE-anti-GATA3, PE-anti-RORγt, PE-Cy7-anti-FoxP3, PE-anti-perforin, APC-anti-granzyme B, and 
PE-Cy7-anti-IFN-γ were used. Antibodies were obtained from BD Pharmingen and eBiosciences. The 
samples were acquired by LSRII (BD Bioscience) and analyzed using the FlowJo software (Tree Star). 
 
Cytotoxicity assay 
CD8+ cells enriched from the spleens of melanoma-bearing mice by mouse T cell enrichment column 
(R&D Systems) and magnetic activated cell separation (MACS) using CD8a microbeads (Miltenyi 
Biotec) as effector cells (0, 5×104, 1×105, 2×105) were co-cultured with GFP tagged B16 cells (2×103) as 
target cells in U-bottom 96-well plates (NUNC) for 72 h. Annexin V/propidium iodide (PI) (BD 
Pharmingen) staining in the large FSC/SSC GFP+ gate was determined by LSRII.  
 
Histology 
The detail procedures of immunohistochemistry were described in chapter 1 report material and methods 
part. Briefly, tumors were harvested and fixed in 10% neutral-buffered formalin. Fixed samples were then 
dehydrated with 70% ethanol, embedded in paraffin, and sectioned at 3 µm. For immunohistochemistry, 
sections were stained with anti-CD8, anti-Eomes, anti-phospho-Smad3 (Abcam), anti-phospho-Smad2 
(Cell Signaling Technology), and anti-Smad4 (Santa Cruz) antibodies. Slides were observed using an 
optical microscope, Imager Z1 (Carl Zeiss). 
 
Immunocytochemistry: Proximity Ligation Assay (PLA) 
The detail procedures of immunocytochemistry were described in chapter 1 report material and methods 
part. Freshly isolated spleen, dLN cells from melanoma-bearing mice were fixed on the slides by 3.7% 
formaldehyde. PLA was performed using the Duolink II Fluorescence kit (OLINK) according to the 
manufacturer’s protocol using the rabbit antibodies against: Smad2, Smad3, phospho-Smad2, 
phospho-Smad3, Smad4, and mouse antibodies against: Smad2/3 and ubiquitin (Cell Signaling 
Technology, BD Bioscience). One respective primary antibody and the secondary antibodies conjugated 
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with oligonucleotides (PLA probe anti-rabbit PLUS and PLA probe anti-rabbit MINUS) were used to 
detect endogenous Smad protein expression for single recognition. Two primary antibodies raised in 
different species and the secondary antibodies conjugated with oligonucleotides (PLA probe anti-rabbit 
PLUS and PLA probe anti-mouse MINUS) were used to detect protein interactions (rabbit anti-Smad2 
and mouse anti-ubiquitin, rabbit anti-Smad3 and mouse anti-ubiquitin, rabbit anti-Smad4 and mouse 
anti-ubiquitin, mouse anti-Smad2/3 and rabbit anti-Smad4). After incubation of the slides with Blocking 
Solution for 30 min at 37°C, they were incubated with primary antibodies diluted in the Antibody Diluent 
overnight at 4°C, in PLA probe solution for 1 h at 37°C and in Ligation-Ligase solution for 30 min at 
37°C with washing with Wash Buffer A in the interim of each step. The slides were incubated in 
Amplification-Polymerase solution for 100 min at 37°C and then washed in Wash Buffer B. To co-stain 
CD8, rat anti-CD8 antibody was added in the Antibody Diluent with primary antibodies for PLA and the 
slide were incubated with Alexa Fluor 488 conjugated anti-rat IgG (Abcam) after washing in Wash Buffer 
B. Nucleus was stained with DAPI. Then, the slides were dried at room temperature in the dark. Slides 
were observed using a confocal microscope, LSM700 (Carl Zeiss). PLA signals were quantified using 
BlobFinder software (Centre for Image Analysis, Uppsala University). 
 
T cell stimulation in vitro  
The detail procedures of T cell isolation were described in chapter 1 report material and methods part. 
Briefly, suspended whole dLN cells (1×106/ml) of melanoma-bearing mice were labeled with CFSE 
(Invitrogen) for stimulation with H-2Db human gp100 peptide (5 µg/ml, Medical and Biological 
Laboratories). After 5 days, CFSE dilution of CD8+ gate was analyzed by flowcytometry. CD8+ or CD4+ 
cells (1×106 cells/ml) enriched from spleens and LNs by MACS using CD4 or CD8a microbeads were 
stimulated with plate-coated anti-CD3 (1 µg/ml) and soluble anti-CD28 (3 µg/ml) antibodies (BD 
Pharmingen) with or without TGF-β1 (5 ng/ml; R&D Systems), EW-7197 (0, 0.5, 1.0, 2.0, 5.0 µM), 
MG-132 (0.5 µM; Sigma-Aldrich) for 3 days in 50 µM 2-mercaptoethanol containing RPMI 1640 media 
in 24-well plates (NUNC).  
 
Western blotting and in vivo ubiquitination assay 
Cells lysed with lysis buffer (PBS containing 0.5% Triton X-100, 20 mM HEPES (pH 7.4), 150 mM 
NaCl, 12.5 mM β-glycerol phosphate, 1.5 mM MgCl2, 10 mM NaF, 2 mM DTT, 1 mM NaOV, 2 mM 
EGTA, 1 mM PMSF, and protease inhibitor cocktail) were electrophoresed on 10% SDS-polyacrylamide 
gel and transferred to PVDF membrane, and probed with antibodies against phospho-Smad2, 
phospho-Smad3 (Abcam), Smad2, Smad3, Smad4 and β-actin (Santa Cruz). Blots were visualized using 
an electrochemiluminescence kit (GE Healthcare). Ubiquitinated Smad4 in CD8+ dLN cells was detected 
using an UbiQapture-Q kit (Enzo Life Sciences) according to the manufacturer’s protocol. Isolated CD8+ 
dLN cells by MACS were pooled (5×106 cells from 5-7 mice/sample) for lysis. Equal amounts of protein 
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of CD8+ LN cells were incubated overnight at 4°C with the UbiQapture-Q matrix beads, which capture 
mono/poly-ubiquitinated proteins. The matrix was then washed and the ubiquitin-protein conjugates were 
eluted by addition of PBS and denaturating buffer. Samples were quenched by incubation for 15 min at 
4°C and then denaturated by heating at 95°C for 10 min. Proteins were eluted in Laemli's sample buffer, 
and subsequently processed for Western blotting with anti-Smad4 antibody (Cell Signaling) and the 
ubiquitin-conjugate antibody supplied by the kit. Ubiquitinated Smad4 in cultured CD8+ T cells was 
detected as previously described (Lee YS et al, 2011). Briefly, CD8+ cells stimulated with 
anti-CD3/CD28 antibodies (2×107 CD8+ cells/sample) were harvested and non-covalent protein 
interactions were dissociated with 1% SDS and boiling for 10 min. Samples were diluted ten times with 
lysis buffer and subsequently suspended using a 1 ml syringe. The samples were cleared by centrifugation 
at 16,000 g for 10 min. Lysates were incubated with protein A/G agarose beads and with anti-Smad4 
antibody (Santa Cruz) at 4 °C for 12-16 h. The beads were washed three times with lysis buffer and 
immunoprecipitates were separated from the beads by adding 2× sample buffer and boiled. 
SDS–PAGE-separated immunoprecipitates were transferred onto PVDF membranes. The membranes 
were denatured with denaturation buffer containing 6 M guanidine chloride, 20 mM Tris (pH 7.5), 100 
mM PMSF, and 5 mM β-mercaptoethanol at 4 °C for 30 min and washed three times with TBST. The 
membranes were blocked with 5 % BSA and incubated with anti-ubiquitin-HRP antibody (Biomol).   
 
Quantitative RT-PCR  
Total RNA extracted using Trizol (Invitrogen) was reverse transcribed with a cDNA Reverse 
Transcription Kit (Invitrogen). Real-time quantitative PCR (triplicate/sample) was performed using an 
ABI 7900 Analyzer with SYBR Green Master Mix (Applied Biosystems) with the primers listed in Table 
4. 
 
Table 4 Primer sequences for quantitative RT-PCR 
 
 
Luciferase assay  
The proximal promoter regions of Eomes were generated by PCR from C57BL/6 genomic DNA using the 
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primers listed in Table 5. Products were verified by sequencing and subcloned into the pGL4 luciferase 
vector (Promega) using KpnI and XhoI sites, XhoI and HindIII sites respectively. The resulting constructs 
were transfected into in vitro-stimulated CD8+ cells along with control thymidine kinase-pRL Renilla 
plasmid (Promega) using Amaxa Nucleofector II (Lonza). Flag-tagged Smad4, with or without 
Flag-tagged Smad2 or Smad3, or an empty pcDNA3 plasmid were co-transfected. At 6 h after 
transfection, cells were restimulated with anti-CD3 and anti-CD28 antibodies as described above for 4 h 
and lysed for luminometer measurements. 
 
Table 5 Primer sequences for the proximal promoter regions of Eomes 
 
 
Chromatin immunoprecipitation (ChIP) 
Chromatin was prepared from 1×107 CD8+ cells isolated from C57BL/6, Cd4Cre;Smad4+/+, and 
Cd4Cre;Smad4fl/fl mice stimulated for 3 days as described above. Immunoprecipitation was performed 
with anti-Smad4 antibody and rabbit IgG using a ChIP Kit (Cell Signaling). Immunoprecipitated DNA 
released from the cross-linked proteins was quantified by real-time quantitative PCR with the primers 
listed in Table 6 and normalized to input DNA.  
 
Table 6 Primer sequences for ChIP 
 
 
Detection of cell cycle and apoptosis of B16 cells 
B16 cells were cultured in the absence or presence of TGF-β (0, 0.5, 1.0, 5.0 ng/ml) and/or EW-7197 (0, 
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0.25, 0.5, 1.0 µM). For cell cycle analysis, DNA content was determined by Propidium iodide (PI) (BD 
Pharmingen). Briefly, B16 cells were fixed by cold 80% ethanol overnight at -20°C. Fixed cells were 
washed twice in phosphate-buffered saline (PBS), 1% bovine serum albumin (BSA), and then 
resuspended in PI solution in PBS containing RNase A (0.1 mg/ml; Sigma-Aldrich). Phosphatidylserine 
exposure was measured using Annexin V Apoptosis Detection Kit APC (eBioscience). B16 cells were 
resuspended in 1× binding buffer (105 cells/100 µl) and incubated with Annexin V-APC for 15 minutes at 
room temperature in the dark. Cells were washed, resuspended in 1× binding buffer (200 µl). Propidium 
iodide (PI) staining solution was added into each sample and analyzed by flowcytometry immediately. 
 
Knockdown of Smurf1 and Smurf2 by shRNA  
The short hairpin RNA (shRNA) sequences specific for endogenous Smurf1 and Smurf2 are described 
previously (Lee YS et al, 2011). To generate shRNAs specific for endogenous Smurf1 and Smurf2, 
double-stranded oligomers containing restriction enzyme sites, a sense sequence, and a loop sequence 
with its antisense sequence were designed and cloned into AgeI and EcoRI sites of the pLKO-puro vector 
(Clontech). Lentiviruses expressing each shRNA were produced by a lentiviral packaging system from 
Invitrogen. Lentivirus expressing mutant Gfp shRNA was used as a negative control for lentivirus 
infection. Expression levels of Smurf1 and Smurf2 mRNA were measured by real-time quantitative PCR 
with the primers: Smurf1 5'-TGCCATCAGCAGATTGAAAG-3', 5'-GTTCCTTCGTTCTCCAGCAG-3', 
Smurf2 5'-GTGAAGAGCTCGGTCCTTTG-3', 5'-TCGCTTGTATCTTGGCACTG-3'  
 
Statistics 
Statistical analyses were performed using analysis tools provided on the VassarStats statistical 
computation site (http://vassarstats.net/). Data were analyzed using the two-tailed unpaired Student’s t test 
and two-way ANOVA test. A P-value <0.05 was considered to indicate statistical significance. 
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Results  
Selective inhibition of ALK5 suppresses the progression of melanoma with enhanced 
CTL activity  
 To examine the therapeutic efficacy of EW-7197 for melanoma in comparison with LY-2157299 for 
eventual use in a Phase 2 clinical trial (Akhurst & Hata, 2012; Calvo-Aller et al, 2008; Hawinkels et al, 
2011), C57BL/6 mice were orally administered with vehicle or vehicle containing EW-7197 (2.5 mg/kg 
daily) or LY-2157299 (75 mg/kg bid) starting from four days after inoculation of GFP-expressing B16 cells 
(4×104) into the left footpads. Low-dose EW-7197 was more efficient than high-dose LY-2157299 in 
suppressing the growth of transplanted tumors (Fig. 34a). Treatment with EW-7197 and LY-2157299 
efficiently suppressed the lymph node (LN) metastases, which were detected by CD11c-CD11b-B220-GFP+ 
cells in the draining lymph nodes (dLNs) (Fig. 34b and Fig. 35).     
 Because TGF-β and EW-7197 showed no direct effects on apoptosis and cell cycle of B16 cells in vitro (Fig. 
36) and TGF-β antagonism mainly targets the immune system rather than the cancer cells (Donkor et al, 
2011; Nam et al, 2008), I we evaluated the effect of EW-7197 on immunophenotypes of melanoma-bearing 
mice. Treatment with EW-7197 increased the proportions and numbers of CD8+ T cells significantly in the 
dLNs (Fig. 34c and 37a), non-dLNs and spleens (Fig. 37b). Other effector T cell subsets were unaltered 
(Fig. 37c). Splenic CD8+ T cells as effector cells were prepared from vehicle- or EW-7197-treated mice for 
co-culture with target B16 cells to examine CTL function. CD8+ T cells from EW-7197-treated mice 
induced significantly more apoptosis of target B16 cells (Fig. 34d). The mRNA expression of the 
cytolytic molecules, perforin, granzyme B, and FasL in whole dLNs and CD8+ dLN cells and protein 
expression of perforin and granzyme B in dLN CD8+ T cells of EW-7197-treated mice increased 
significantly (Fig. 34e, 34f, 37d and 37e).  
 To confirm whether enhanced CD8+ T cell responses by EW-7197 are antigen-specific, I stimulated the 
carboxyfluorescein diacetate succinmidyl ester (CFSE)-labeled dLN cells with gp100 peptide, a 
melanosomal differentiation Ag expressed by melanomas and melanocytes (Thomson et al, 1988) and 
determined CFSE dilution of CD8+ gate by flowcytometry. CD8+ cells from EW-7197-treated mice 
showed significantly enhanced proliferation compared with CD8+ cells from vehicle-treated mice (Fig. 
34g). Tumor-infiltrating lymphocytes (TILs) increased significantly in the melanomas of 
EW-7197-treated mice, which were rarely observed in those of vehicle-treated mice (Fig. 34h and Fig. 
37f). Especially, CD8+ cell infiltration was remarkable in the melanomas of EW-7197-treated mice, which 
was absent in those of vehicle-treated mice (Fig. 34h and i). These data show that oral administration of a 
novel ALK5 inhibitor, EW-7197 has a potent therapeutic effect on B16 melanoma by upregulating CTL 
activities. 
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Figure 34 Oral administration of ALK5 inhibitors suppresses melanoma and LN metastases with 
enhanced CTL activity.  
C57BL/6 mice were treated with vehicle or EW-7197 (2.5 mg/kg daily) (n = 15/group) /LY-2157299 (75 
mg/kg bid) (n = 5) from 4 days after inoculation of GFP-expressing B16 cells (4×104) into the left footpads. 
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Data are shown as mean ± or + SEM. P values were calculated by 2-tailed unpaired Student’s t test or by 
two-way ANOVA test for A. 
(a) Chronological tumor volumes (left), tumor weights on day 21 (right). (b,c) The % of GFP+ B16 cells 
(medians ± interquartile) and immune cell subsets in dLNs were determined by flowcytometry. (d) 
Target cytolysis at the indicated ratios of effector CD8+ T cells: target B16 cells was evaluated by 
Annexin V/PI. (e) qPCR analyses for mRNA levels of the cytolytic molecules in CD8+ dLN cells (n = 
5/group). (f) Histograms show CD8+ gate with MFI. Graphs show the % of positive cells in CD8+ gate (n 
= 10/group). (g) Proliferation of CD8+ dLN cells stimulated with gp100 peptide was assessed by CFSE 
dilution. (h) Representative CD4/8 dot plots of TILs. Graphs show the % of CD4+ or CD8+ cells in the 
Ficoll-enriched cells (n = 8/group). (i) Representative immunohistochemistry sections of inoculated 
melanomas (scale bar: 100 µm). Arrows indicate CD8+ cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35 Dot plots by FACS analyses show GFP+CD11c-, GFP+CD11b-, GFP+B220- cells in the 
dLNs of melanoma-bearing mice three weeks after inoculation. 
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Figure 36 TGF-β does not affect apoptosis and cell cycle of B16 cells.  
B16 cells were treated with TGF-β (0, 0.5, 1.0, 5.0 ng/ml) or EW-7197 (0, 0.25, 0.5, 1.0 µM) for 72 h. (a) 
Apoptosis was determined by Annexin V and PI staining. (b) Cell cycle was determined by PI staining 
using flow cytometry. 
 67 
 
 
Figure 37 Oral administration of EW-7197 suppresses melanoma and LN metastases with enhanced 
CTL activity.  
Data are shown as mean + SEM (n = 5-10/group). P values were calculated by 2-tailed unpaired Student’s 
t test. (a) Total and CD8+ cell numbers of LNs and spleens in the melanoma-bearing mice. Representative 
dot plots of CD4/8 are shown. (b) Percentages of CD4/8 subsets in the non-dLNs and spleens. (c) 
Percentages of effector T cell subsets in the dLNs. (d,e) qPCR analyses for mRNA levels of the cytolytic 
molecules in the dLNs and the non-dLNs. (f) Representative FSC/SSC contour plots of enriched 
tumor-infiltrated cells by density gradient centrifugation.  
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ALK5 inhibition downregulates Smad4 in melanoma-bearing mice 
 I next confirmed the blockade of TGF-β signaling by EW-7197 in vivo. Cells of dLNs and spleens from 
melanoma-bearing mice were immediately fixed for proximity ligation assay (PLA) to quantify 
endogenous Smad protein levels in vivo by single recognition protocol or to quantify protein interactions. 
EW-7197 blocked phosphorylation of Smad2 and Smad3 in dLN cells, while the expression levels of 
Smad2 and Smad3 were intact (Fig. 38a-d). Although phosphorylation of R-Smads is often monitored to 
confirm the efficacy of TGF-β antagonists (Donkor et al, 2011), their effect on Smad4 has not been 
evaluated. Treatment with EW-7197 blocked the interaction between Smad2/3 and Smad4 (Fig. 38e). 
Moreover, I found that EW-7197 significantly reduced Smad4 protein in both nucleus and cytoplasm of 
dLN cells (Fig. 38f). The same pattern was confirmed in spleens of EW-7197-treated mice and dLNs of 
LY-2157299-treated mice (Fig. 39 and 40a-d). Western blot analysis confirmed the reduction in Smad4 
protein and R-Smad phosphorylation with intact R-Smad expression in dLNs and CD8+ dLN cells by 
ALK5 inhibitors (Fig. 38g and 40e). However, EW-7197 did not affect Smad4 mRNA (Fig. 38h), 
indicating that EW-7197 did not downregulate Smad4 at the transcriptional level. Reduction in Smad4 
protein was most remarkable in CD8+ T cells (Fig. 38g and i). 
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Figure 38 EW-7197 downregulates Smad4 and blocks R-Smad phosphorylation in melanoma 
-bearing mice.  
Data are shown as mean + SEM (n = 5/group). P values were calculated by 2-tailed unpaired Student’s t 
test. (a-f) PLA (red) show the expression of phosho-Smad2, phosho-Smad3, Smad2, Smad3, Smad4, and 
the interaction between Smad2/3 and Smad4 in dLN cells co-stained with anti-CD8 (green) (scale bars: 5 
µm, 50 µm). Graphs show mean PLA signals quantified using BlobFinder software. (g) Western blots show 
Smads in whole or CD8+ dLN cells from EW-7197-treated or vehicle-treated melanoma-bearing mice (2-3 
mice/group). (h) qPCR analyses for Smad4 mRNA levels of dLN cells. (i) Graph shows the % of the 
Smad4 PLA+ cells in CD8- and CD8+ dLN cells.  
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Figure 39 Oral administration of EW-7197 inhibits TGF-β signaling and downregulates Smad4 in 
spleen cells of melanoma-bearing mice.  
(a-d) Expression of phospho-Smad2, phospho-Smad3, Smad4, and the interaction between Smad2/3 and 
Smad4 from EW-7197-treated mice was determined by PLA. Images were acquired by confocal 
microscope, LSM700 (scale bars: 5 µm, 50 µm). Graphs show the quantification of the red dots 
expressed in nucleus and cytoplasm. Data are shown as mean + SEM (n = 5/group). P values were 
calculated by 2-tailed unpaired Student’s t test.  
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Figure 40 Oral administration of LY-2157299 inhibits TGF-β signaling and downregulates Smad4 
in dLN cells of melanoma-bearing mice.  
(a-d) Expression of phospho-Smad2, phospho-Smad3, Smad4, and the interaction between Smad2/3 and 
Smad4 in dLN cells from vehicle- or LY-2157299-treated mice was determined by PLA. Images were 
acquired by confocal microscope, LSM700 (scale bars: 5 µm, 50 µm). (e) Smad4 and β-Actin in dLN 
cells from vehicle- or LY-2157299-treated mice were detected by Western blotting.  
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ALK5 inhibition induces ubiquitin-mediated degradation of Smad4 in 
melanoma-bearing mice 
 Ubiquitination is a post-translational modification of proteins, which plays a key role in TGF-β signal 
transduction by regulating Smad protein levels (De Boeck et al, 2012; Izzi et al, 2004). PLA detected the 
significantly increased interaction of ubiquitin with Smad4 in dLN cells, especially in CD8+ T cells of the 
melanoma-bearing mice treated with EW-7197 or LY-2157299 (Fig. 41a and 42). By contrast, neither 
Smad2 nor Smad3 interacted with ubiquitin in dLN cells of both vehicle- and EW-7197-treated mice (Fig. 
43). Endogenous ubiquitinated Smad4 captured by UbiQapture-Q matrices was increased in CD8+ dLN 
cells from EW-7197-treated mice (Fig. 41b). Consistently, EW-7197 also induced downregulation of 
Smad4 protein in CD8+ T cells stimulated with anti-CD3/CD28 antibodies in vitro, but not in CD4+ T cells, 
although it inhibited R-Smad phosphorylation in both CD4+ and CD8+ T cells (Fig. 41c). A proteasome 
inhibitor, MG-132 abolished EW-7197-induced downregulation of Smad4 in CD8+ T cells (Fig. 41c), 
indicating that the ubiquitin-proteasomal system is responsible for Smad4 protein degradation. EW-7197 
induced ubiquitination of Smad4 in activated CD8+ T cells in a dose dependent manner (Fig. 41d). Unlike 
CD8+ T cells, treatment with EW-7197 did not affect Smad4 protein expression in both transplanted B16 
melanoma in vivo and B16 melanoma cells in vitro, despite the inhibition of R-Smad phosphorylation (Fig. 
41e and f).  
 Among the E3 ubiquitin ligases, which modulate TGF-β signaling, Smurf2 is upregulated by IL-7 in 
CD8+ T cells (Pellegrini et al, 2009). However, knockdown of Smurf1 and/or Smurf2 by shRNA did not 
affect Smad4 downregulation by EW-7197 in CD8+ T cells (Fig. 44). 
 Taken together, systemic ALK5 inhibition in melanoma-bearing mice blocks TGF-β signaling by not only 
inhibiting R-Smad phosphorylation, but also inducing ubiquitin-mediated degradation of Smad4 protein 
in immune cells, especially in CD8+ T cells, but not in melanoma cells. 
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Figure 41 ALK5 inhibition induces ubiquitin-mediated degradation of Smad4 in CD8+ T cells in 
melanoma-bearing mice.   
(a) PLA (red) show ubiquitinated Smad4 in the dLN cells co-stained with anti-CD8 (green) (scale bars: 5 
µm, 50 µm).  
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(b) Western blot shows endogenous ubiquitinated Smad4 in CD8+ dLN cells captured using an 
UbiQaptureTM-Q kit. (c) Western blots show Smads in CD4+ and CD8+ cells stimulated with 
anti-CD3/CD28 with/without EW-7197 and/or MG-132 for 3 days. (d) IP-Western blot shows 
endogenous ubiquitinated Smad4 in CD8+ cells stimulated with anti-CD3/CD28 with/without EW-7197 
and/or MG-132 for 3 days.  (e) Representative immunohistochemistry sections of inoculated melanomas 
(scale bar: 100 µm). (f) Smad4 protein in B16 cells was detected by PLA (red) (scale bars: 10 µm) (left). 
Western blots show Smads in B16 cells cultured with EW-7197 with or without TGF-β1 (right). 
 
 
 
 
 
 
 
 
Figure 42 LY-2157299 induces Smad4 ubiquitination in dLN cells of melanoma-bearing mice.  
Interaction between Smad4 and ubiquitin in dLN cells of vehicle- or LY-2157299-treated 
melanoma-bearing mice was determined by PLA. Images were acquired by confocal microscope, 
LSM700 (scale bars: 5 µm, 50 µm).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43 R-Smads are not ubiquitinated in dLN cells of EW-7197-treated melanoma-bearing 
mice.  
Interaction between Smad2 and ubiquitin or Smad3 and ubiquitin in dLN cells of vehicle- or 
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EW-7197-treated melanoma-bearing mice was determined by PLA. Images were acquired by confocal 
microscope, LSM700 (scale bars: 5 µm, 50 µm).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44 Smurf1 and Smurf2 are not involved in degradation of Smad4 by ALK5 inhibition.  
Knockdown of Smurf1 and/or Smurf2 by shRNA was confirmed by qPCR. Western blots show Smad4 
and β-Actin in CD8+ T cells stimulated with anti-CD3/28 antibodies with or without EW-7197 in vitro.  
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T cell-specific Smad4 deletion suppresses the progression of melanoma with 
enhanced CTL activity 
 Similarly with Smad4 downregulation by EW-7197 treatment, the orthotopic B16 melanoma model using 
T cell-specific Smad4 knockout mice (Kim et al, 2006) showed significant suppression of melanoma 
growth and LN metastases (Fig. 45a and b). CD8+ T cells increased significantly in the dLNs (Fig 45c), 
non-dLNs, and spleens (Fig. 46a) of Cd4Cre;Smad4fl/fl (Smad4-/-) mice. Other effector T cell subsets were 
unaltered by the Smad4 genotypes (Fig. 46b). The cytotoxicity assay showed significantly more B16 lysis 
by Smad4-/- CD8+ T cells (Fig. 45d). The mRNA and protein expression of cytolytic molecules increased 
significantly in whole dLNs and CD8+ dLN cells of Smad4-/- mice, as in EW-7197-treated mice (Fig. 45e, f 
and 46c).  
 Stimulation with gp100 peptide induced significantly more proliferation of CD8+ dLN cells from 
Smad4-/- mice compared with Cd4Cre;Smad4+/+ (Smad4+/+) mice (Fig. 45g). TILs increased significantly 
in the melanomas of Smad4-/- mice, which were rarely observed in those of Smad4+/+ mice (Fig. 45h and  
46d). Especially, CD8+ cell infiltration was remarkable in the melanomas of Smad4-/- mice, which was 
absent in those of Smad4+/+ mice (Fig. 45h and i). These data are essentially identical to those obtained 
from EW-7197-treated mice, suggesting that TGF-β suppresses antigen-specific CTL functions via Smad4 
without affecting other effector T cell subsets, and that treatment with EW-7197 phenocopies the effect of 
T-cell specific Smad4 knockout. 
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Figure 45 T cell-specific Smad4 deletion suppresses melanoma and LN metastases with enhanced 
CTL activity. GFP-expressing B16 cells were inoculated into the left footpads of Cd4Cre;Smad4+/+, 
Cd4Cre;Smad4+/fl, and Cd4Cre;Smad4fl/fl mice. Data are shown as mean ± or + SEM (n = 5-8/genotype). P 
values were calculated by 2-tailed unpaired Student’s t test or by two-way ANOVA test for (a). (a) 
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Chronological tumor volumes (left), tumor weights on day 21 (right). (b,c) The % of GFP+ B16 cells 
(medians ± interquartile) and immune cell subsets in dLNs were determined by flowcytometry. (n = 
25/genotype). (d) Cytolysis at the indicated ratios of effector CD8+ T cells: target B16 cells. (e) qPCR 
analyses for mRNA levels of the cytolytic molecules in CD8+ dLN cells (n = 5/genotype). (f) Histograms 
show CD8+ gate with MFI. Graphs show the % of positive cells in CD8+ gate (n = 25/genotype). (g) 
Proliferation of CD8+ dLN cells stimulated with gp100 peptide was assessed by CFSE dilution. (h) 
Representative CD4/8 dot plots of TILs. Graphs show the % of CD4+ or CD8+ cells in the Ficoll-enriched 
cells (n = 5/genotype). (i) Representative immunohistochemistry sections of inoculated melanomas (scale 
bar: 100 µm). Arrows indicate CD8+ cells.  
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Figure 46 T cell-specific Smad4 deletion suppresses melanoma and LN metastases with enhanced 
CTL activity.  
Data are shown as mean + SEM (n = 25/group). P values were calculated by 2-tailed unpaired Student’s t 
test. (a) Percentages of immune cell subsets in the non-dLNs and spleens (n = 25/genotype). (b) 
Percentages of effector T cell subsets in the dLNs. (c) qPCR analyses for mRNA levels of the cytolytic 
molecules in the dLNs. (d) Representative FSC/SSC contour plots of enriched tumor-infiltrated cells by 
density gradient centrifugation. 
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ALK5 inhibition and T cell-specific Smad4 deletion upregulate Eomes in CD8+ T 
cells of melanoma-bearing mice  
 To address underlying mechanisms of enhanced CTL activity by Smad4 downregulation, I examined the 
master transcription factors for CTLs, T-bet and Eomes. T-bet suppresses metastases (Peng et al, 2004), and 
TGF-β1 suppresses T-bet and IFN-γ in CD4+ T cells (Park et al, 2007). However, expression of neither 
T-bet nor IFN-γ in CD8+ T cells was affected (Fig. 47a and b). Instead, I found that Eomes+ CD8+ T cells 
increased significantly in dLNs of melanoma-bearing mice by the treatment with EW-7197, LY-2157299, 
or T cell-specific Smad4 deletion (Fig. 47a, b and 48a-c). Eomes mRNA expression in dLNs and CD8+dLN 
cells also increased significantly by EW-7197 or T cell-specific Smad4 deletion (Fig. 47c and 48d). 
Expression of Eomes in CD4+ T cells was very low in any melanoma-bearing mice (Fig. 49). CD8+ TILs in 
EW-7197-treated or Smad4-/- mice expressed high levels of Eomes (Fig. 47d). Significantly more Eomes+ 
cells infiltrated into the melanomas by EW-7197 or T cell-specific Smad4 deletion (Fig. 47e). Proportions 
of TIL subsets except T cells in EW-7197-treated or Smad4-/- mice were unaltered compared with the 
controls (Fig. 50). These data suggest that Smad4-mediated TGF-β signaling suppresses CTLs by specific 
downregulation of Eomes. 
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Figure 47 Upregulation of Eomes in CD8+ T cells of melanoma-bearing mice by the treatment with 
ALK5 inhibitors and T cell-specific Smad4 deletion.  
Data are shown as mean + SEM. P values were calculated by 2-tailed unpaired Student’s t test. (a) 
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Representative histograms show Eomes, T-bet, and IFN-γ expression in CD8+ dLN cells with MFI. (b) 
Graphs show the % of positive cells in CD8+ dLN cells of EW-7197 (n = 10) or LY-2157299 (n = 5) 
treated or Cd4Cre;Smad4+/+ and Cd4Cre;Smad4fl/fl (n = 10/genotype) melanoma-bearing mice. (c) qPCR 
analyses for mRNA levels in CD8+ dLN cells (n = 5/group, n = 5/genotype). (d) Representative 
Eomes/IFN-γ dot plots of CD8+ gated TILs. Graphs show the % of positive cells in the Ficoll-enriched 
cells (n = 8/group, n = 5/genotype). (e) Representative immunohisochemistry sections of inoculated 
melanomas (scale bar: 100 µm). Arrows indicate Eomes+ cells. 
 
Figure 48 Upregulation of Eomes in CD8+ T cells by ALK5 inhibition or T cell-specific Smad4 
deletion.  
(a) Representative dot plots show the expression of Eomes, T-bet, and IFN-γ _in dLN CD8+ cells of 
vehicle- or EW-7197-treated melanoma-bearing mice. (b) Representative dot plots show the expression 
of Eomes, T-bet, and IFN-γ _in dLN CD8+ cells of Cd4Cre;Smad4+/+ or Cd4Cre;Smad4fl/fl mice. (c) 
Representative histograms show the expression of Eomes, T-bet, and IFN-γ _in dLN CD8+ cells of 
vehicle- or LY-2157299-treated melanoma-bearing mice. (d) qPCR analyses for mRNA levels in dLN 
cells of vehicle- or EW-7197-treated melanoma-bearing and Cd4Cre;Smad4+/+ or Cd4Cre;Smad4fl/fl mice 
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(n = 10/group, n = 10/genotype).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49 Eomes is not expressed in CD4+ cells in the dLNs of melanoma-bearing mice. 
Representative dot plots show the expression of IFN-γ _and Eomes in CD4+ cells from vehicle-treated, 
EW-7197-treated, Cd4Cre;Smad4+/+, Cd4Cre;Smad4+/fl, and Cd4Cre;Smad4fl/fl mice.  
 
 
 
 
 
 
 
 
 
 
Figure 50 Characterization of TILs.  
TILs subsets in melanomas of control, EW-7197-treated or Smad4-/- mice were determined by 
flowcytometry. Graphs show the percentages of positive cells. (a) Percentages of immune cell subsets in 
TIL gates were determined by flowcytometry. (b) Percentages of T-bet+ or Foxp3+CD25+ in CD4+ TIL 
gates were determined by flowcytometry.  
 84 
 
Anti-melanoma effect of EW-7197 depends on CD8+ T cells 
 To confirm whether CD8+ T cells are necessary for anti-melanoma effect of EW-7197, I deleted CD8+, 
CD4+ or NK cells in C57BL/6 mice inoculated with GFP-expressing B16 cells (2×105). Intraperitoneal 
injection of anti-CD8, anti-CD4, or anti-asialo GM1 antibody efficiently deleted the specific cell 
compartment, respectively (Fig. 51b-d and 52a). EW-7197 significantly suppressed tumor growth even 
with this aggressive protocol (Fig. 51a). Deletion of CD8+, CD4+ or NK cells did not affect tumor growth 
in the absence of EW-7197 treatment (Fig. 51a-d). Anti-tumor effect of EW-7197 was completely 
abolished on deletion of CD8+ cells, rather, EW-7197 slightly exacerbated tumor growth in CD8+-deleted 
mice (Fig. 51b and e). In contrast, EW-7197 showed significant anti-tumor efficacy on deletion of CD4+ 
cells or NK cells (Fig 51c-e). In NK-deleted mice, I observed approximately 40% reduction in the 
efficacy of EW-7197 on tumor growth and CD8+ T cell expansion (Fig. 51d-f), suggesting that EW-7197 
exerts the efficacy partially via NK cells, similarly to the previous report on the efficacy of the 
neutralizing anti-TGF-β antibody 1D11 on a mouse 4T1 model of metastatic breast cancer (Nam et al, 
2008). Treatment with EW-7197 resulted in a significant increase in CD8+ T cells with upregulated 
Eomes expression in CD4+-deleted and NK-deleted mice as well as control (Fig. 51f, g and 52b). These 
data verify the previous reports that anti-tumor effect of the TGF-β antagonism mainly depends on CD8+ 
T cells (Donkor et al, 2011; Gorelik et al, 2001; Nam et al, 2008; Zhang et al, 2005). 
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Figure 51 CD8+ T cells are necessary for anti-melanoma effect of EW-7197.  
C57BL/6 mice were i.p. injected with control, anti-CD8, anti-CD4, or anti-asialo GM1 antibody at day -4, 
0, 7, and 14 of melanoma inoculation (day 0), with vehicle or EW-7197 from 4 days after inoculation of 
GFP-expressing B16 cells (2×105) into the left lower abdomen (n = 5-8/group). Data are shown as mean ± 
or + SEM. P values were calculated by 2-tailed unpaired Student’s t test or by two-way ANOVA test. 
(a-d) Chronological tumor volumes of the mice treated with the indicated antibodies. (e) The efficacy of 
EW-7197 following each antibody treatment was expressed as a  % of the maximum therapeutic effect 
seen in the intact system (control IgG). (f) The % of CD8+ cells in dLNs were determined by 
flowcytometry. (g) Histograms show the expression of Eomes in CD8+dLN cells. The graph shows the % 
of Eomes+ in CD8+dLN cells were determined by flowcytometry.  
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Figure 52 Deletion of CD8+ T cells, CD4+ T cells, NK cells in vivo.  
C57BL/6 mice were i.p. injected with control, anti-CD8, anti-CD4, or anti-asialo GM1 antibody at day -4, 
0, 7, and 14 of melanoma inoculation (day 0), with vehicle or EW-7197 from 4 days after inoculation of 
GFP-expressing B16 cells (2´105) into the left lower abdomen (n = 5-8/group). Data are shown as mean + 
SEM. (a) Representative dot plots are shown for each antibody treatment. (b) Graphs show the 
percentages of immune cell subsets. 
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Long-term systemic administration of EW-7197 and T cell-specific Smad4 deletion 
maintain normal immune homeostasis 
 I determined whether Smad4 downregulation by ALK5 inhibition or gene deletion causes 
pro-inflammatory untoward effects because T cell-specific Smad4 deficient mice with mixed backgrounds 
(C57BL/6, Sv129, and FVB) develop inflammation and carcinogenesis in gastrointestinal tract (Hahn et al, 
2011; Kim et al, 2006). Cd4Cre;Smad4+/fl mice were backcrossed to C57BL/6 strain for eight generations 
and confirmed the deletion of the Smad4 gene in both CD4+ and CD8+ T cells (Fig. 54). C57BL/6 mice were 
treated with vehicle or vehicle containing EW-7197 (2.5 mg/kg daily) for 8 weeks. The proportions and 
numbers of immune cells, naïve/memory CD4+/CD8+ T cells, and Treg in the spleens and superficial LNs 
of vehicle-treated or Smad4+/+ mice were comparable to those of EW-7197-treated mice or Smad4-/- mice at 
16 week-old (Fig. 53a-c). Low expression levels of Eomes and T-bet in steady-state CD8+ T cells were not 
altered by EW-7197 or T cell-specific Smad4 deletion (Fig. 53d). Consistent with normal immune 
homeostasis by lifetime exposure to a soluble TGF-β antagonist (Yang et al, 2002), treatment with 
EW-7197 for 8 weeks maintained normal immune homeostasis (Fig. 53a-d). 
 Thus, long-term systemic administration of EW-7197 or T cell-specific Smad4 deletion did not affect 
systemic immune homeostasis in C57BL/6 mice without melanoma challenge in a specific pathogen-free 
(SPF) environment. 
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Figure 53 Normal immune homeostasis by long-term systemic administration of EW-7197 or T 
cell-specific Smad4 deletion.  
Immune cell populations in the spleens and superficial LNs of C57BL/6 mice treated with vehicle or 
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vehicle containing EW-7197 (2.5 mg/kg daily) for 8 weeks (n = 5/group), Cd4Cre;Smad4+/+, 
Cd4Cre;Smad4+/fl and Cd4Cre;Smad4fl/fl mice (n = 15/genotype) at 16 weeks of age were analyzed by 
flowcytometry. Graphs show mean + SEM. No statistical significance was observed by 2-tailed unpaired 
Student’s t test. (a-c) Graphs show the cell numbers of immune cell subsets, naïve/memory CD4+/CD8+ T 
cells, and Foxp3+CD25+CD4+ cells in the spleens and superficial LNs determined by flowcytometry. (d) 
Graph shows the % of Eomes+ in CD8+ gate. Representative dot plots show the expression of Eomes and 
T-bet in CD8+ gate. 
 
 
 
 
 
 
 
 
Figure 54 T cell-specific Smad4 deletion.  
Genomic DNA was obtained from CD3+ T cells, CD4+ T cells, and CD8+ T cells sorted by MACS from 
the spleens and superficial LNs of Cd4Cre;Smad4+/+, Cd4Cre;Smad4+/fl, and Cd4Cre;Smad4fl/fl mice. 
Deletion of the Smad4 gene was confirmed by PCR by the primers reported in the references (Kim et al, 
2006; Lee et al, 2001; Yang et al, 1999).  
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TGF-β suppresses Eomes via Smad4 and Smad3 in CD8+ T cells 
 I examined the effect of Smad4 deficiency on the expression of IFN-γ, T-bet, and Eomes in CD8+ T cells 
stimulated with anti-CD3 and anti-CD28 antibodies in vitro. Consistent with the in vivo data, Smad4-/- CD8+ 
T cells expressed significantly higher levels of Eomes than those in Smad4+/+ CD8+ T cells (Fig. 55a). 
TGF-β1 (5 ng/ml) completely suppressed Eomes in Smad4+/+ CD8+ T cells, whereas the suppressive effect 
of TGF-β1 on Eomes was partially impaired in Smad4-/- CD8+ T cells (Fig. 55a). However, TGF-β1 and 
Smad4 deficiency had only a slight effect on T-bet in CD8+ T cells (Fig. 55b). Stimulation with 
phorbol-12-myristate-13-acetate (PMA) and ionomycin showed the same trend (Fig. 56). 
 I activated CD8+ T cells from Cd4Cre;Smad2+/+/Cd4Cre;Smad2fl/fl or Smad3+/+/Smad3-/- mice in vitro to 
examine which R-Smad was responsible for Smad4-mediated suppression of Eomes. Eomes+ cells 
increased significantly in the absence of Smad3, but not Smad2 (Fig. 55c). Deficiency of Smad3 showed the 
intermediate effect between deficiency of Smad2 and Smad4 on the increase of Eomes+ cells. 
 I examined the effects of Smad deficiency on mRNA expression of granzyme B and FasL in CD8+ T cells 
because Eomes upregulates these cytolytic molecules (Pearce et al, 2003). Consistent with the in vivo 
expression patterns, Eomes, granzyme B, and FasL mRNA levels in Smad4-/- CD8+ T cells were 
significantly higher than those in Smad4+/+ CD8+ T cells, whereas T-bet and IFN-γ mRNA levels in 
Smad4-/- CD8+ T cells were similar to those in Smad4+/+ CD8+ T cells (Fig. 55d). Eomes, granzyme B, and 
FasL mRNA levels were unaltered in Smad2-/- CD8+ T cells, whereas those in Smad3-/- CD8+ T cells were 
intermediate between Smad4-/- and Smad2-/- CD8+ T cells (Fig. 55d).  
 Effector CTL differentiation occurs in two sequential phases, early induction of T-bet and late induction 
of Eomes (Cruz-Guilloty et al, 2009). Smad4 deficiency did not affect T-bet mRNA, which peaked at 12 
h (Fig 55e). By contrast, late induction of Eomes (48, 72 h), granzyme B and FasL mRNA (72 h) was 
further upregulated in Smad4-/- CD8+ T cells (Fig. 55e). Thus, TGF-β signaling through Smad4 does not 
affect T-bet even at the early phase. Taken together, TGF-β signaling through Smad4 and Smad3, but not 
Smad2, suppresses Eomes and the cytolytic molecules. 
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Figure 55 TGF-β signaling through Smad4 and Smad3 suppresses Eomes and the cytolytic 
molecules in CD8+ T cells.  
CD8+ cells from the indicated mice were stimulated with anti-CD3/CD28 with or without TGF-β1 for 3 
days. Data are shown as mean ± or + SEM. P values were calculated by 2-tailed unpaired Student’s t test. 
(a-c) Representative dot plots show Eomes/IFN-γ, T-bet/IFN-γ in CD8+ cells from 
Cd4Cre;Smad4+/+/Cd4Cre;Smad4fl/fl mice and Eomes/IFN-γ in CD8+ cells from 
Cd4Cre;Smad2+/+/Cd4Cre;Smad2fl/fl, and Smad3+/+/Smad3-/- mice (n = 5-7/genotype). (d,e) qPCR 
analyses (n = 5/genotype) for T-bet, Eomes, IFN-γ, granzyme B, and FasL mRNA levels in CD8+ cells 
from Cd4Cre;Smad4fl/fl/Cd4Cre;Smad2fl/fl/Smad3-/-/control mice at 72 h and Cd4Cre;Smad4+/+ 
/Cd4Cre;Smad4fl/fl mice at the indicated time points.  
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Figure 56 Effect of Smad4 on PMA/ionomycin-stimulated CD8+ T cells.  
CD8+ cells from the indicated mice were stimulated with PMA and ionomycin for 3 days. (a,b) 
Representative dot plots show Eomes/IFN-γ, T-bet/IFN-γ _in CD8+ cells from Cd4Cre;Smad4+/+ 
/Cd4Cre;Smad4fl/fl mice (n = 2/genotype). (c) qPCR analyses for Eomes, T-bet, and IFN-γ  mRNA 
levels in CD8+ cells from Cd4Cre;Smad4+/+/Cd4Cre;Smad4fl/fl mice (n = 2/genotype).  
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Smad4 represses the Eomes gene in CD8+ T cells  
 I next assessed the direct transcriptional regulation of the Eomes gene by Smads in CD8+ T cells using 
luciferase assays. Smad4 inhibited Eomes-luc activity (-2.0 kb) in a dose dependent manner (Fig. 57a). 
Smad4 inhibited Eomes-luc activity to the same level as TGF-β1 (5 ng/ml), whereas Smad3 inhibited it to a 
lesser degree, and Smad2 was inactive (Fig. 57b). Smad2 reversed, whereas Smad3 further enhanced, the 
inhibitory effect of Smad4 on Eomes-luc activity (Fig. 57b). Thus, Smad4 is the main repressor and Smad3 
is the corepressor of the Eomes gene.  
 To screen the Smad4 binding regions in the Eomes promoter, I generated serial truncated luciferase 
reporter constructs (Fig. 57c). Inhibition of luciferase activity by Smad4 was abolished in a -0.37 kb 
reporter construct, whereas a -0.7 kb construct remained susceptible to Smad4 inhibition (Fig. 57c), 
indicating that the Smad4 binding sites are located between -0.37 kb and -0.7 kb. Screening Smad-binding 
sequence, CAGAC (Massague et al, 2005) by ChIP showed that Smad4 bound to (-680 to -499) and 
(-538 to -321) in the Eomes proximal promoter (Fig. 57d). Specificity of Smad4 pull-down was confirmed 
by completely abolished enrichment at these sites in Smad4-/- CD8+ T cells (Fig. 57d). Thus, Smad4 binds 
to the proximal promoter of the Eomes gene, thereby repressing its transcription in CD8+ T cells. 
 
Figure 57 Smad4 binds to the Eomes promoter to repress transcription.  
(a-c) C57BL/6 CD8+ cells stimulated with anti-CD3/CD28 for 3 days were transfected with the Eomes 
luciferase reporter construct with various dosages of Smad4, Smad2, Smad3, and Smad4, or the various 
truncated Eomes luciferase reporter constructs with or without Smad4. TGF-β1 was treated as a control.  
(d) CD8+ cells from Cd4Cre;Smad4+/+ and Cd4Cre;Smad4fl/fl mice were stimulated with anti-CD3/CD28 
for 3 days, lysed, and immunoprecipitated with either anti-Smad4 or rabbit IgG. Bound DNA was 
measured by qPCR using primers specific to the Eomes promoter. Graphs show mean + SEM (n = 3). 
Differential occupancy fold changes from four independent experiments are shown. 
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Summary 
Among TGF-β antagonisms, ALK5 inhibition induced ubiquitin-mediated degradation of Smad4 in CD8+ T 
cells in addition to the direct inhibition of R-Smad phosphorylation to enhance anti-melanoma CTL 
responses through derepressing Eomes (Fig. 58). 
 
 
Figure 58 ALK5 Inhibition suppresses melanoma by inducing ubiquitin degradation of Smad4, 
thereby derepressing anti-tumor CTL activity.   
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Discussion  
It has been well documented that systemic TGF-β antagonism mainly targets CD8+ T cells in cancer 
(Nam et al, 2008) and selective blockade of TGF-β signaling in pan T cells or CD8+ T cells is sufficient to 
eradicate tumors (Donkor et al, 2011; Gorelik et al, 2001; Zhang et al, 2005). Meanwhile, the precise 
molecular mechanisms whereby TGF-β antagonists enhance T cell-mediated anti-tumor immunity remain 
unknown. Here, I show that ALK5 inhibition by LY-2157299 and a novel ALK5 inhibitor, EW-7197 
induced ubiquitin-mediated degradation of Smad4 protein in immune cells, most profoundly in CD8+ T 
cells. However, pharmacologic ALK5 inhibition did not affect Smad4 protein in melanoma cells, 
although cell-autonomous TGF-β antagonism affects melanoma progression (Javelaud et al, 2005). 
TGF-β signaling pathway is controlled by ubiquitin protein modification (De Boeck et al, 2012; Izzi et al, 
2004). Various E3 Ub ligases, such as Smurfs, WWP1, NEDD4-2, CHIP, and SCF target Smad4 for 
degradation to negatively regulate TGF-β signaling (Li et al, 2004; Moren et al, 2005; Wan et al, 2004). 
Jab1 antagonizes TGF-β function by inducing uniquitin-mediated degradation of Smad4 (Wan M et al, 
2002). Although R-Smads are also controlled by ubiquitin-mediated degradation (De Boeck et al, 2012; 
Izzi et al, 2004), ALK5 inhibitors did not reduce R-Smads. Ubiquitnation of proteins by E3 ligases has 
emerged as an indispensable signaling pathway that regulates T-cell tolerance (Paolino et al, 2009). I 
investigated the possible involvement of Smurf, because IL-7 modulates TGF-β signaling via Smurf 2 
activity in CD8+ T cells (Pellegrini et al, 2009). However, Smurf1/2 were found to be irrelevant to Smad4 
degradation by ALK5 inhibition in CD8+ T cells (Fig. 44). Future studies are required for elucidating 
precise mechanisms whereby ALK5 inhibition induces ubiquitin-mediated degradation of Smad4 
specifically in CD8+ T cells. 
 EW-7197 and T cell-specific Smad4 gene targeting enhanced anti-tumor CTL responses with specific 
upregulation of Eomes in melanoma-bearing mice. CD8+ T cells lacking the Smad2/3/4 genes and the 
promoter analyses showed that Smad4 was the main repressor of the Eomes gene. As reported that Smad2 
and Smad3 had distinct regulatory effects in epithelial cells and Th17 cells despite of their high homology 
(Brown et al, 2007; Martinez et al, 2009; Martinez et al, 2010), Smad3, but not Smad2 had an additive 
effect on transcriptional repression of Eomes by Smad4. By contrast, it has been reported that TGF-β 
suppresses Eomes via Smad2/3-independent, JNK-dependent signaling in Th17 induction (Ichiyama et al, 
2011; Takimoto et al, 2010). Discrepancy between their reports and my study might be due to several 
reasons: TGF-β signaling pathways to suppress Eomes might be different between CD4+ and CD8+ T cell 
effector subsets, Smad4 was not investigated in their reports, they used T cells from 
LckCreSmad2fl/flSmad3-/- (Smad2/3-DKO) or LckCreSmad2fl/flSmad3+/- (Smad2cKO/Smad3hetero) mice, 
so that Smad4 alone or Smad4 and haploid expression of Smad3 could still transduce TGF-β signaling to 
repress the Eomes gene according to my findings (Fig. 57a and b). They speculated JNK-dependent, 
Smad2/3-independent pathway from the similar attenuating effect of ALK5 inhibitor, SB431542 and JNK 
inhibitor, SP600125 on Eomes repression in T cells stimulated with TCR and TGF-β. However, 
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specificity of ALK5 inhibitors for Smad-mediated TGF-β signaling pathway (Akhurst & Hata, 2012; 
Flavell et al, 2010; Hawinkels et al, 2011; Jin et al, 2011) and cooperation of Smad3 and Smad4 with 
c-Jun/c-Fos to mediate TGF-β-induced transcription (Zhang et al, 1998) suggest that both Smad3/4 and 
JNK pathways are involved in TGF-β-induced Eomes suppression.  
 Although TGF-β suppresses the cytolytic genes and IFN-γ by a mechanism involving R-Smads and 
ATF1 (Thomas et al, 2005) and Eomes as well as IFN-γ and cytolytic molecules are regulated by Runx3 
(Cruz-Guilloty et al, 2009), Smad4 did not regulate IFN-γ production by CD8+ T cells in my model. 
Because Runx3 is known to cooperate with Smad3/4 to regulate target genes (Pardali et al, 2000; Zhang 
et al, 2000), Smad4 might be required for Runx3 to regulate IFN-γ, but not Eomes and cytolytic 
molecules. Recent findings revealed the melanoma-promoting effects of IFN-γ (Cho et al, 2011; Zaidi et 
al, 2011). Thus, the ability to upregulate CTL functions without affecting IFN-γ would prove safety and 
efficacy of ALK5 inhibition for anti-melanoma therapy. However, cell-specific regulatory mechanisms of 
IFN-γ and T-bet by TGF-β remain to be determined because TGF-β suppresses IFN-γ and T-bet via 
MAPK-dependent, Smad3-independent signaling in CD4+ T cells (Park et al, 2007), whereas TGF-β 
suppresses IFN-γ and T-bet via Smad2/3/4-mediated signaling in NK cells (Tinoco et al, 2009).    
 Efficacy of ALK5 inhibition on a relatively immunogenic B16 melanoma model depends fully on CD8+ 
T cells because deletion of CD8+ T cells resulted in 100% loss in the efficacy of EW-7197 on tumor 
progression (Fig. 51b and e). Although NK cell deletion showed partial reduction in the efficacy of 
EW-7197 (Fig. 51d and e), ALK5 inhibition did not upregulate Eomes in NK cells (data not shown). In a 
relatively non-immunogenic 4T1 model, anti-TGF-β antibodies suppress metastasis via cooperative 
effects on multiple cellular components: CD8+ T cells, NK cells, and tumor cells (Nam et al, 2008). 
Therefore, immunogenicity of tumors is presumably the crucial factor to affect the potency of TGF-β 
antagonism on the specific cellular targets in anti-tumor therapy; nevertheless enhancement of CD8+ 
T-cell mediated anti-tumor immune response is the main outcome of TGF-β antagonism even in the 
non-immunogenic tumor. 
 TGF-β also regulates effector CD4+ T cell subsets (Li et al, 2006). However, downregulation of Smad4 
by neither ALK5 inhibition nor T cell-specific gene targeting affected any CD4+ T cell subsets in 
melanoma-bearing mice. Although TGF-β inhibits T-bet (Park et al, 2007) and Eomes (Narayanan et al, 
2010) in Th1 cells, Smad4 downregulation had no effect on T-bet and Eomes in CD4+ T cells. Similarly 
with my model, systemic TGF-β antagonism by IN-1130, one of the prototype ALK5 inhibitors in the 
same structural family as EW-7197 ameliorates experimental autoimmune encephalomyelitis by local 
actions without affecting systemic peripheral immune reactions including the generation of Th17 (Luo et 
al, 2007). Concerning Tregs, one of the major suppressors of anti-tumor immune surveillance (Flavell et 
al, 2010), Smad4-independent development of Tregs in my model and Smad2/3-independent development 
of nTregs in vivo (Gu et al, 2012) indicate that Treg development is Smad-independent. Thus, systemic 
TGF-β antagonism seems to target the disease-specific major pathogenic immune effector cells in 
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inflammatory lesions without affecting systemic immune homeostasis. Further investigation is required to 
determine the distinct targets of systemic TGF-β antagonism in various diseases. 
 One major concern for pharmacologic Smad4 downregulation is the possibility of the gastrointestinal 
inflammation and spontaneous carcinogenesis that was observed in mice in which Smad4 was targeted in 
T cell-specific and systemic inducible routes (Hahn et al, 2011; Karlsson et al, 2007; Kim et al, 2006). 
However, T cell-specific Smad4 deletion by Cd4Cre recombinase transgene with C57BL/6 background 
showed a normal phenotype at least by 6 months of age in my SPF facilities. Moreover, even the complete 
Smad4 knockout in T cells took time to develop carcinogenesis (Hahn et al, 2011; Kim et al, 2006). 
Considering the short in vivo half-life of EW-7197 and maintenance of normal immune homeostasis by 
lifetime exposure to a soluble TGF-β antagonist (Yang et al, 2002), the risk of gastrointestinal 
inflammation and carcinogenesis by temporal or intermittent prescription of EW-7197 is expected to be 
low.  
 Several ALK5 inhibitors are currently at pre-clinical and clinical stages for various cancers including 
melanoma (Akhurst & Hata, 2012; Flavell et al, 2008; Hawinkels et al, 2011; Mohammad et al, 2011). 
Because orally administered EW-7197 was more efficacious than LY-2157299 (75 mg/kg bid) against 
melanoma at a dose as low as 2.5 mg/kg daily, EW-7197 is the good candidate as the next generation 
ALK5 inhibitor for anti-melanoma therapy. 
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Conclusion  
  
 Immune system is existed for protecting our body against diseases and disorders from enemies. It is 
regulated by many kinds of factors such as cytokine and chemokine. Among them, TGF-β has been 
characterized as a critical immune regulatory cytokine. In my doctoral dissertation, I report the novel 
TGF-β signaling mechanisms for Th17 differentiation in rheumatoid arthritis and for suppressing CTL 
responses in melanoma. First, I found the novel dynamic signaling networks of R-SMADs-STAT3-ERK 
in arthritogenic Th17 differentiation, which has revised the classical linear signaling cascades (Levy ED 
et al, 2010). Second, systemic ALK5 inhibition has a potent therapeutic efficacy against melanoma by 
inducing the ubiquitin-mediated degradation of Smad4, thereby relieving suppressive effect of 
Smad3/Smad4-mediated TGF-β signaling on Eomes in CTLs. These findings suggest that 
SMAD-mediated TGF-β signaling orchestrate effector T cell development and function in 
cell-type-specific manners. 
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